<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2015-10-01" updated="2020-01-02">
  <drugbank-id primary="true">DB09154</drugbank-id>
  <drugbank-id>DB09159</drugbank-id>
  <name>Sodium citrate</name>
  <description>Sodium citrate is the sodium salt of citric acid. It is white, crystalline powder or white, granular crystals, slightly deliquescent in moist air, freely soluble in water,&#13;
practically insoluble in alcohol. Like citric acid, it has a sour taste. &#13;
From the medical point of view, it is used as alkalinizing agent. It works by neutralizing excess acid in the blood and urine. It has been indicated for the treatment of metabolic acidosis.</description>
  <cas-number>68-04-2</cas-number>
  <unii>RS7A450LGA</unii>
  <average-mass>258.068</average-mass>
  <monoisotopic-mass>257.97283534</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A19410</ref-id>
        <pubmed-id>17883701</pubmed-id>
        <citation>Mann KG, Whelihan MF, Butenas S, Orfeo T: Citrate anticoagulation and the dynamics of thrombin generation. J Thromb Haemost. 2007 Oct;5(10):2055-61.</citation>
      </article>
      <article>
        <ref-id>A19411</ref-id>
        <pubmed-id>25535411</pubmed-id>
        <citation>Palta S, Saroa R, Palta A: Overview of the coagulation system. Indian J Anaesth. 2014 Sep;58(5):515-23. doi: 10.4103/0019-5049.144643.</citation>
      </article>
      <article>
        <ref-id>A19414</ref-id>
        <pubmed-id>14530750</pubmed-id>
        <citation>Kramer L, Bauer E, Joukhadar C, Strobl W, Gendo A, Madl C, Gangl A: Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit Care Med. 2003 Oct;31(10):2450-5.</citation>
      </article>
      <article>
        <ref-id>A19415</ref-id>
        <pubmed-id>23824037</pubmed-id>
        <citation>Zheng Y, Xu Z, Zhu Q, Liu J, Qian J, You H, Gu Y, Hao C, Jiao Z, Ding F: Citrate Pharmacokinetics in Critically Ill Patients with Acute Kidney Injury. PLoS One. 2013 Jun 18;8(6):e65992. doi: 10.1371/journal.pone.0065992. Print 2013.</citation>
      </article>
      <article>
        <ref-id>A19419</ref-id>
        <pubmed-id>26131288</pubmed-id>
        <citation>Li K, Xu Y: Citrate metabolism in blood transfusions and its relationship due to metabolic alkalosis and respiratory acidosis. Int J Clin Exp Med. 2015 Apr 15;8(4):6578-84. eCollection 2015.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L788</ref-id>
        <title>FDA Monograph: Sodium Citrate Tablet</title>
        <url>https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a60660b2-c5db-45a0-885f-de93e655380d</url>
      </link>
      <link>
        <ref-id>L789</ref-id>
        <title>FDA Monograph: Sodium Citrate Liquid</title>
        <url>https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eb0bade0-fc86-4bfa-90cc-f0d5f7b4d3a8</url>
      </link>
      <link>
        <ref-id>L790</ref-id>
        <title>TOXNET: Trisodium Citrate</title>
        <url>https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+5201</url>
      </link>
      <link>
        <ref-id>L795</ref-id>
        <title>SMPDB: Citric Acid Cycle</title>
        <url>http://smpdb.ca/view/SMP00057</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Used as an anticoagulant during plasmophoresis as well as a neutralizing agent in the treatment of upset stomach and acidic urine [FDA Label] [L788] [L789].</indication>
  <pharmacodynamics>Citrate prevents activation of the clotting cascade by chelating calcium ions. Citrate neutralizes acid in the stomach and urine, raising the pH [L790].&#13;
</pharmacodynamics>
  <mechanism-of-action>Citrate chelates free calcium ions preventing them from forming a complex with tissue factor and coagulation factor VIIa to promote the activation of coagulation factor X [A19410] [A19411]. This inhibits the extrinsic initiation of the coagulation cascade. Citrate may also exert an anticoagulant effect via a so far unknown mechanism as restoration of calcium concentration does not fully reverse the effect of citrate [A19410]. Citrate is a weak base and so reacts with hydrochloric acid in the stomach to raise the pH. It it further metabolized to bicarbonate which then acts as a systemic alkalizing agent, raising the pH of the blood and urine [L790]. It also acts as a diuretic and increases the urinary excretion of calcium.</mechanism-of-action>
  <toxicity>Overdose toxicity is mainly due to alkalosis as well as tetany or depressed heart function due to lack of free calcium [L790].&#13;
</toxicity>
  <metabolism>Citrate is metabolized to bicarbonate in the liver and plays a role as an intermediate in the citric acid cycle [A19419] [L795].</metabolism>
  <absorption>Tmax of 98-130min [A19414].</absorption>
  <half-life>18-54 min [A19414]</half-life>
  <protein-binding/>
  <route-of-elimination>Largely eliminated through hepatic metabolism with very little cleared by the kidneys [A19414] [A19415].</route-of-elimination>
  <volume-of-distribution>19-39L [A19414].</volume-of-distribution>
  <clearance>Total clearance of 313-1107mL/min [A19414].</clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as tricarboxylic acids and derivatives. These are carboxylic acids containing exactly three carboxyl groups.</description>
    <direct-parent>Tricarboxylic acids and derivatives</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organic acids and derivatives</superclass>
    <class>Carboxylic acids and derivatives</class>
    <subclass>Tricarboxylic acids and derivatives</subclass>
    <alternative-parent>Carbonyl compounds</alternative-parent>
    <alternative-parent>Carboxylic acid salts</alternative-parent>
    <alternative-parent>Carboxylic acids</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organic sodium salts</alternative-parent>
    <alternative-parent>Tertiary alcohols</alternative-parent>
    <substituent>Alcohol</substituent>
    <substituent>Aliphatic acyclic compound</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxylic acid</substituent>
    <substituent>Carboxylic acid salt</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Organic alkali metal salt</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organic salt</substituent>
    <substituent>Organic sodium salt</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Tertiary alcohol</substituent>
    <substituent>Tricarboxylic acid or derivatives</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT002410</drugbank-id>
      <name>Sodium citrate dihydrate</name>
      <unii>B22547B95K</unii>
      <cas-number>6132-04-3</cas-number>
      <inchikey>NLJMYIDDQXHKNR-UHFFFAOYSA-K</inchikey>
      <average-mass>294.098</average-mass>
      <monoisotopic-mass>293.99396471</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">Anhydrous sodium citrate</synonym>
    <synonym language="english" coder="">Anhydrous trisodium citrate</synonym>
    <synonym language="english" coder="">Citric acid, trisodium salt</synonym>
    <synonym language="latin" coder="">Natrii citras</synonym>
    <synonym language="english" coder="">Natrocitral</synonym>
    <synonym language="english" coder="">Sodium citrate anhydrous</synonym>
    <synonym language="english" coder="">Sodium citrate, anhydrous</synonym>
    <synonym language="english" coder="">Sodium citrate,anhydrous</synonym>
    <synonym language="english" coder="">trisodium citrate anhydrous</synonym>
    <synonym language="english" coder="">Trisodium citrate, anhydrous</synonym>
    <synonym language="english" coder="">Trisodium-citrate</synonym>
  </synonyms>
  <products>
    <product>
      <name>A-C-D Solution</name>
      <labeller>Draximage A Division Of Draxis Specialty Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00108081</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1959-12-31</started-marketing-on>
      <ended-marketing-on>2003-07-08</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Acd A</name>
      <labeller>Terumo BCT Ltd</labeller>
      <ndc-id/>
      <ndc-product-code>14537-967</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-02-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BA010228</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Acd A</name>
      <labeller>Terumo Bct, Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>14537-817</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-02-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BA010228</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Acd A</name>
      <labeller>Terumo Bct, Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>14537-815</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-02-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BA010228</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ACD Blood-Pack Units (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-9001</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN160918</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Acd-A</name>
      <labeller>Haemonetics Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>53157-796</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-11-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>NDA710497</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Acd-A</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-0641</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN160918</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Acd-A</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-9005</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN160918</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Additive Formula 3</name>
      <labeller>Terumo Bct, Ltd</labeller>
      <ndc-id/>
      <ndc-product-code>14537-824</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-05-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN001214</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Additive Formula 3</name>
      <labeller>Terumo Bct, Ltd</labeller>
      <ndc-id/>
      <ndc-product-code>14537-826</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-05-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN001214</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Additive Formula 3</name>
      <labeller>Terumo Bct, Ltd</labeller>
      <ndc-id/>
      <ndc-product-code>14537-828</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-05-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN001214</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Additive Solution Formula 3 As-3</name>
      <labeller>Terumo Bct, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02324393</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Unknown</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6470</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6492</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-05-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6477</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6493</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-05-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6444</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6445</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6430</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6439</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6436</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6431</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6464</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6457</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6461</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6459</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6449</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6462</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6458</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6475</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6453</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6484</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-06-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6482</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-06-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6487</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-06-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6483</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-02-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6495</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6466</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6494</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6488</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6486</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6489</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6485</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-06-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6496</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6501</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-03-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6502</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6499</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-09-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adsol Red Cell Preservation System In Plastic Container (pl 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6504</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adsol Red Cell Preservation System In Plastic Container (pl 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6506</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adsol Red Cell Preservation System In Plastic Container (pl 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6508</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adsol Red Cell Preservation System In Plastic Container (pl 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6507</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Amo Endosol Solution</name>
      <labeller>Amo Canada Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02007967</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intraocular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Anticoagulant Cit Phos Dex Adenine Sol USP</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01960865</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-10-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Anticoagulant Citrate Dextr Sol Formula A USP</name>
      <labeller>Cutter Med &amp; Biol, Division Of Miles Canada Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00743496</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1988-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-09</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Anticoagulant Citrate Dextrose A</name>
      <labeller>Citra Labs</labeller>
      <ndc-id/>
      <ndc-product-code>23731-6051</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-08-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Extracorporeal</route>
      <fda-application-number>BN020037</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Anticoagulant Citrate Dextrose A ACD-A</name>
      <labeller>Arteriocyte Medical Systems, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43203-852</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Extracorporeal</route>
      <fda-application-number>BA110057</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Anticoagulant Citrate Dextrose Solution USP (acd) Formula A</name>
      <labeller>Fresenius Kabi Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00788139</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Unknown</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Anticoagulant Citrate Dextrose Solution USP (acd) Formula A</name>
      <labeller>Terumo Bct, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02469731</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-06-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Unknown</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Anticoagulant Citrate Dextrose Solution USP (acd) Formula B</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00788112</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-31</started-marketing-on>
      <ended-marketing-on>2012-07-14</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Unknown</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Anticoagulant Citrate Dextrose Solution-A</name>
      <labeller>Biomet Biologics</labeller>
      <ndc-id/>
      <ndc-product-code>23731-6040</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-01-01</started-marketing-on>
      <ended-marketing-on>2010-09-06</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Extracorporeal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Anticoagulant Citrate Phosphate Dextrose (CPD) Blood-Pack Units in PL 146 Plastic</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-9202</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN170401</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Anticoagulant Citrate Phosphate Dextrose (CPD) Blood-Pack Units in PL 146 Plastic</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-9201</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN170401</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Anticoagulant Sod Citrate Soltn 4gm/100ml</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00060313</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Unknown</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Anticoagulant Sodium Citrate</name>
      <labeller>Medsep Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>62646-798</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-04-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>10 g/250mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA760305</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Anticoagulant Sodium Citrate</name>
      <labeller>Laboratorios Grifols Sa</labeller>
      <ndc-id/>
      <ndc-product-code>76297-006</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-10-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>40 mg/1mL</strength>
      <route>Extracorporeal</route>
      <fda-application-number>BA125697</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Anticoagulant Sodium Citrate 4% W/V Solution, USP</name>
      <labeller>Haemonetics Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02377411</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Unknown</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Anticoagulant Sodium Citrate Sol 4% USP</name>
      <labeller>Cutter Med &amp; Biol, Division Of Miles Canada Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00572357</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1988-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-09</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Anticoagulant Sodium Citrate Solution USP</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02344416</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Unknown</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Anticoagulant Solution Citrate Phosphate Dextrose (cpd)</name>
      <labeller>Maco Pharma</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02444100</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Unknown</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>As 3</name>
      <labeller>Terumo BCT Ltd</labeller>
      <ndc-id/>
      <ndc-product-code>14537-966</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-05-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN001214</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Balanced Salt</name>
      <labeller>Akorn</labeller>
      <ndc-id/>
      <ndc-product-code>17478-921</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA075503</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Balanced Salt</name>
      <labeller>Akorn</labeller>
      <ndc-id/>
      <ndc-product-code>17478-920</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA075503</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Balanced Salt</name>
      <labeller>B. Braun Medical Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0264-2514</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Irrigation</route>
      <fda-application-number>ANDA091387</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Balanced Salt Solution</name>
      <labeller>Hospira Healthcare Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00708127</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-12-31</started-marketing-on>
      <ended-marketing-on>2012-08-03</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Irrigation</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Balanced Salt Solution</name>
      <labeller>Pharma Stulln Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02023709</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Irrigation</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Blood Pack Unit Cpd</name>
      <labeller>Fenwal Labs, Division of Baxter Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00273953</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1969-12-31</started-marketing-on>
      <ended-marketing-on>1998-08-14</ended-marketing-on>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Bromo Seltzer</name>
      <labeller>Warner Lambert Canada Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00376469</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1976-12-31</started-marketing-on>
      <ended-marketing-on>1999-08-13</ended-marketing-on>
      <dosage-form>Powder</dosage-form>
      <strength>3.5 g</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Bronchodex Fort-DM Syr</name>
      <labeller>Therapex Division De E Z Em Canada Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00506141</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1980-12-31</started-marketing-on>
      <ended-marketing-on>1997-07-22</ended-marketing-on>
      <dosage-form>Syrup</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Bss</name>
      <labeller>ALCON LABORATORIES, INC.</labeller>
      <ndc-id/>
      <ndc-product-code>0065-1795</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1969-03-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>NDA020742</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Bss</name>
      <labeller>ALCON LABORATORIES, INC.</labeller>
      <ndc-id/>
      <ndc-product-code>0065-0795</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1969-03-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>NDA020742</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Bss Sterile Irrigating Solution</name>
      <labeller>Alcon, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00512990</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1980-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Citrocarbonate Eff Pws</name>
      <labeller>Roberts Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01971948</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on>1999-03-31</ended-marketing-on>
      <dosage-form>Granule, effervescent</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Cpd</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-9206</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN170401</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpd Adenine Cpda 1</name>
      <labeller>Fenwal Labs, Division of Baxter Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00516775</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1981-12-31</started-marketing-on>
      <ended-marketing-on>1997-08-11</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Cpd Solution</name>
      <labeller>Laboratorios Grifols s.a.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02421135</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Unknown</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Cpd/adsol</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6476</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpd/adsol</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6505</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpd/adsol</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6503</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN811104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>CPD/ADSOL Red Cell Preservation Solution System (PL 2209)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6479</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-01-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN900223</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>CPD/ADSOL Red Cell Preservation Solution System (PL 2209)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6481</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN900223</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>CPD/ADSOL Red Cell Preservation Solution System (PL 2209)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6478</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-01-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN900223</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6343</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6331</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6344</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6332</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6336</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6309</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6320</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6308</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6316</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-06-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6319</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6305</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6317</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6301</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6307</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6312</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6321</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6326</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6327</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6329</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6328</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6322</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-06-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-6330</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-9393</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-9395</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-9304</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-9394</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cpda-1</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-9398</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN770420</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>CPDA-1 Blood Collection System</name>
      <labeller>Haemonetics Manufacturing Inc</labeller>
      <ndc-id/>
      <ndc-product-code>53157-730</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1980-11-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN800077</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>CPDA-1 Blood Collection System</name>
      <labeller>Haemonetics Manufacturing Inc</labeller>
      <ndc-id/>
      <ndc-product-code>53157-130</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1980-11-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN800077</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>CVS Health Nausea Relief</name>
      <labeller>CVS Pharmacy,Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69842-423</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, chewable</dosage-form>
      <strength>230 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cytosol Ophthalmics - Balanced Salt Solution</name>
      <labeller>Biomet Biologics</labeller>
      <ndc-id/>
      <ndc-product-code>23731-8000</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-01-01</started-marketing-on>
      <ended-marketing-on>2010-09-04</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Irrigation</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cytra 3</name>
      <labeller>Pegasus Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>55246-002</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-05-05</started-marketing-on>
      <ended-marketing-on>2009-10-17</ended-marketing-on>
      <dosage-form>Syrup</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cytra 3</name>
      <labeller>Cypress Pharmaceuticals, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>60258-002</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-07-29</started-marketing-on>
      <ended-marketing-on>2014-10-11</ended-marketing-on>
      <dosage-form>Syrup</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cytra-2</name>
      <labeller>Pegasus Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>55246-001</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-05-05</started-marketing-on>
      <ended-marketing-on>2010-12-30</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cytra-2</name>
      <labeller>Cypress Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>60258-001</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-01</started-marketing-on>
      <ended-marketing-on>2014-10-11</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dalmacol</name>
      <labeller>Laboratoire Riva Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02230769</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-03-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Syrup</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dalmacol</name>
      <labeller>Laboratoire Atlas Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00507407</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Syrup</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>EnLyte</name>
      <labeller>Jaymac Pharmaceuticals Llc</labeller>
      <ndc-id/>
      <ndc-product-code>64661-711</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-08-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, delayed release pellets</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Haemonetics Additive Solution Formula 3 (AS-3)</name>
      <labeller>Haemonetics Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>57826-460</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Extracorporeal</route>
      <fda-application-number>BN000127</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Haemonetics Additive Solution Formula 3 (AS-3)</name>
      <labeller>Haemonetics Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>57826-462</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Extracorporeal</route>
      <fda-application-number>BN000127</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Haemonetics Anticoagulant Citrate Dextrose Solution</name>
      <labeller>Haemonetics Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>57826-426</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Extracorporeal</route>
      <fda-application-number>BA980728</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Haemonetics Anticoagulant Citrate Phosphate Double Dextrose Solution (CP2D)</name>
      <labeller>Haemonetics Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>57826-455</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Extracorporeal</route>
      <fda-application-number>BN000127</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Haemonetics Anticoagulant Sodium Citrate</name>
      <labeller>Haemonetics Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>57826-420</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>40 mg/1mL</strength>
      <route>Extracorporeal</route>
      <fda-application-number>BN980123</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>IMUFLEX WB-RP Blood Bag System with Integral Whole Blood Leukocyte Reduction Filter (Removing Platelets) with Diversion Blood Sampling Arm Anticoagulant Citrate Phosphate Dextrose (CPD) AND OPTISOL (AS-5) Red Cell Preservative</name>
      <labeller>Terumo Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>53877-006</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN880217</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>IMUFLEX WB-SP BLOOD BAG SYSTEM with Integral Whole Blood Leukocyte Reduction Filter (Saving Platelets) with Diversion Blood Sampling Arm</name>
      <labeller>Terumo Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>53877-010</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN880217</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>IMUFLEX WB-SP Blood Bag System with Integral Whole Blood Leukocyte Reduction Filter (Saving Platelets) with Diversion Blood Sampling Arm Anticoagulant Citrate Phosphate Dextrose (CPD) and OPTISOL (AS-5) Red Cell Preservative</name>
      <labeller>Terumo Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>53877-007</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN880217</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>InterSol</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-9601</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN080041</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>InterSol</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-9602</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN080041</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Iocare Balanced Salt Solution</name>
      <labeller>Iolab Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00760064</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-09</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intraocular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lemon Eno 2650mg/pck</name>
      <labeller>Smithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02038234</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on>1998-08-25</ended-marketing-on>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Leucoflex CGP</name>
      <labeller>Maco Productions</labeller>
      <ndc-id/>
      <ndc-product-code>14498-002</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN040083</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Leukotrap WB System</name>
      <labeller>Haemonetics Manufacturing Inc</labeller>
      <ndc-id/>
      <ndc-product-code>53157-736</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1980-11-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN800077</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Leukotrap WB System</name>
      <labeller>Haemonetics Manufacturing Inc</labeller>
      <ndc-id/>
      <ndc-product-code>53157-136</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1980-11-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN800077</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lytren</name>
      <labeller>Mead Johnson Nutritionals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00654957</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1985-12-31</started-marketing-on>
      <ended-marketing-on>2003-07-08</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lytren Rhs Liq</name>
      <labeller>Mead Johnson Nutritionals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00841803</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-12-31</started-marketing-on>
      <ended-marketing-on>2000-09-11</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mercodol With Decapryn</name>
      <labeller>Aventis Pharma Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02048183</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on>2001-07-20</ended-marketing-on>
      <dosage-form>Syrup</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Metrate</name>
      <labeller>Medic Laboratory LtÉe</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00230200</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1963-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-09</ended-marketing-on>
      <dosage-form>Syrup</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Microlax Micro Enema</name>
      <labeller>Mcneil Consumer Healthcare Division Of Johnson &amp; Johnson Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02063905</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Enema; Liquid</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Microlax Micro-enema</name>
      <labeller>Kabi Pharmacia Canada Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02004666</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-10</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>MTL1 Leucoflex</name>
      <labeller>Maco Productions</labeller>
      <ndc-id/>
      <ndc-product-code>14498-001</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-11-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN040083</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nauzene</name>
      <labeller>Alva Amco Pharmacal Companies, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52389-172</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-02-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Syrup</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part357</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nauzene</name>
      <labeller>Alva-Amco Pharmacal Companies, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52389-142</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-07-08</started-marketing-on>
      <ended-marketing-on>2010-05-04</ended-marketing-on>
      <dosage-form>Tablet, chewable</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part357</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nauzene</name>
      <labeller>Alva-Amco Pharmacal Companies, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52389-242</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-07-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, chewable</dosage-form>
      <strength>230 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nauzene Grape</name>
      <labeller>Alva-Amco Pharmacal Companies, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52389-629</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-04-24</started-marketing-on>
      <ended-marketing-on>2012-04-24</ended-marketing-on>
      <dosage-form>Syrup</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part331</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nauzene Grape</name>
      <labeller>Alva-Amco Pharmacal Companies, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52389-729</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-04-24</started-marketing-on>
      <ended-marketing-on>2014-01-03</ended-marketing-on>
      <dosage-form>Syrup</dosage-form>
      <strength>0.921 g/15mL</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neo Tuss Syr</name>
      <labeller>Neolab Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00440884</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1979-12-31</started-marketing-on>
      <ended-marketing-on>2007-07-27</ended-marketing-on>
      <dosage-form>Syrup</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Nutricel Additive System - CP2D</name>
      <labeller>Medsep Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>62646-120</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>NDA820915</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Odan Balanced Salt Solution</name>
      <labeller>Odan Laboratories Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00622893</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1985-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Irrigation</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Oracit</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-7352</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-07</started-marketing-on>
      <ended-marketing-on>2018-05-07</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Oracit</name>
      <labeller>Cmp Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>46287-014</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-05-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Oracit</name>
      <labeller>Carolina Medical Products Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00722472</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-12-31</started-marketing-on>
      <ended-marketing-on>1999-07-26</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Orange Eno 2645mg/pck</name>
      <labeller>Smithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02038226</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on>1998-08-25</ended-marketing-on>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pleo Alkala Antacid</name>
      <labeller>Sanum Kehlbeck GmbH &amp; Co. KG</labeller>
      <ndc-id/>
      <ndc-product-code>60681-6001</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-12-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part331</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Potassium Citrate-Sodium Citrate-Citric Acid</name>
      <labeller>Method Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>58657-411</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-20</started-marketing-on>
      <ended-marketing-on>2015-12-31</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Potassium Citrate-Sodium Citrate-Citric Acid</name>
      <labeller>Method Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>58657-311</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-21</started-marketing-on>
      <ended-marketing-on>2016-03-03</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>PramLyte</name>
      <labeller>Allegis Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>28595-400</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-11</started-marketing-on>
      <ended-marketing-on>2016-01-04</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA078604</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Puralor</name>
      <labeller>Centurion Labs</labeller>
      <ndc-id/>
      <ndc-product-code>23359-700</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-01</started-marketing-on>
      <ended-marketing-on>2017-09-20</ended-marketing-on>
      <dosage-form>Tablet, chewable</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ratio-calmydone</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00550477</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1981-12-31</started-marketing-on>
      <ended-marketing-on>2017-04-04</ended-marketing-on>
      <dosage-form>Syrup</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Rehydralyte</name>
      <labeller>Ross Laboratories, Division Of Abbott Laboratories Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00763195</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1988-12-31</started-marketing-on>
      <ended-marketing-on>2008-04-16</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sodium Citrate</name>
      <labeller>Haemonetics Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>53157-798</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1978-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>10.0 g/250mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA760305</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Citrate 4% w/v Anticoagulant</name>
      <labeller>Terumo Bct, Ltd</labeller>
      <ndc-id/>
      <ndc-product-code>14537-881</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-06-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 g/100mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BA125608</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Citrate and Citric Acid</name>
      <labeller>Atlantic Biologicals Corps.</labeller>
      <ndc-id/>
      <ndc-product-code>17856-0595</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1969-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Citrate and Citric Acid</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-9419</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1969-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Citrate and Citric Acid</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-9410</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1969-01-01</started-marketing-on>
      <ended-marketing-on>2019-10-31</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Citrate and Citric Acid</name>
      <labeller>Pharmaceutical Associates, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0121-0595</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1969-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Citrate and Citric Acid</name>
      <labeller>Pharmaceutical Associates, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0121-1190</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1969-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Citrate and Citric Acid</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-5777</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1969-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Citrate Blood Pack Units, (PL 146 Plastic)</name>
      <labeller>Fresenius Kabi USA, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>63323-505</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>4 g/100mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BN770923</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Citrate Blood-Pack Units, (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-9502</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>2 g/50mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BN770923</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Citrate Blood-Pack Units, (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-9505</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>4 g/100mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BN770923</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Citrate Blood-Pack Units, (PL 146 Plastic)</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-9504</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>4 g/100mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BN770923</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Citrate-Citric Acid</name>
      <labeller>Method Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>58657-410</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-20</started-marketing-on>
      <ended-marketing-on>2015-12-31</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Citrate-Citric Acid</name>
      <labeller>Method Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>58657-310</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-21</started-marketing-on>
      <ended-marketing-on>2016-03-03</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Solucion InterSol</name>
      <labeller>Fenwal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0942-9603</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN080041</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ssp+</name>
      <labeller>Maco Pharma</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02492067</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ssp+</name>
      <labeller>Maco Pharma</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02492075</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sterile Cord Blood Collection Unit</name>
      <labeller>Medsep Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>62646-791</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-03-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>NDA800222</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sterile Cord Blood Collection Unit (MSC127D)</name>
      <labeller>Maco Productions</labeller>
      <ndc-id/>
      <ndc-product-code>14498-003</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-12-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN125552</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sterile Cord Blood Collection Unit (MSC128D)</name>
      <labeller>Maco Productions</labeller>
      <ndc-id/>
      <ndc-product-code>14498-004</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-12-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN125552</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TERUFLEX Blood Bag System Anticoagulant Citrate Phosphate Dextrose (CPD) AND OPTISOL Red Cell Preservative</name>
      <labeller>Terumo Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>53877-005</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-12-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN880217</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TERUFLEX Blood Bag System Anticoagulant Citrate Phosphate Dextrose Adenine (CPDA-1)</name>
      <labeller>Terumo Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>53877-001</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-05-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN820528</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TERUFLEX Blood Bag System with Blood Sampling Arm Anticoagulant Citrate Phosphate Dextrose (CPD) AND OPTISOL (AS-5) Red Cell Preservative</name>
      <labeller>Terumo Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>53877-009</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN880217</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TERUFLEX Blood Bag System with Diversion Blood Sampling Arm Anticoagulant Citrate Phosphate Dextrose (CPD) AND OPTISOL (AS-5) Red Cell Preservative</name>
      <labeller>Terumo Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>53877-008</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BN880217</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>triCitrasol</name>
      <labeller>Citra Labs LLC</labeller>
      <ndc-id/>
      <ndc-product-code>23731-6030</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>14 g/30mL</strength>
      <route>Extracorporeal</route>
      <fda-application-number>BN010409</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tricitrates</name>
      <labeller>Pharmaceutical Associates, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0121-0677</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-05-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tricitrates</name>
      <labeller>Atlantic Biologicals Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>17856-0677</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Virtrate-2</name>
      <labeller>Virtus Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>76439-367</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-05-15</started-marketing-on>
      <ended-marketing-on>2017-05-30</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Virtrate-2</name>
      <labeller>Virtus Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>69543-367</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-17</started-marketing-on>
      <ended-marketing-on>2016-09-30</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Virtrate-3</name>
      <labeller>Virtus Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>76439-366</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-05-15</started-marketing-on>
      <ended-marketing-on>2017-05-30</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Virtrate-3</name>
      <labeller>Virtus Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>69543-366</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-07</started-marketing-on>
      <ended-marketing-on>2016-09-30</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vito Bronches Sirop</name>
      <labeller>Duchesnay Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00412651</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1977-12-31</started-marketing-on>
      <ended-marketing-on>2006-07-27</ended-marketing-on>
      <dosage-form>Syrup</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Cytra-2</name>
      <ingredients>Citric acid + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Cytra 3</name>
      <ingredients>Citric acid + Potassium citrate + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Anticoagulant Citrate Dextrose Solution-A</name>
      <ingredients>Citric acid + Dextrose, unspecified form + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Cytosol Ophthalmics - Balanced Salt Solution</name>
      <ingredients>Calcium chloride + Magnesium chloride + Potassium chloride + Sodium acetate + Sodium chloride + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Pleo Alkala Antacid</name>
      <ingredients>Potassium bicarbonate + Sodium bicarbonate + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Nauzene</name>
      <ingredients>Dextrose, unspecified form + Fructose + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Anticoagulant Sodium Citrate</name>
      <ingredients>Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Oracit</name>
      <ingredients>Citric acid + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cytra-2</name>
      <ingredients>Citric acid + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Citrate</name>
      <ingredients>Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Acd-A</name>
      <ingredients>Citric acid + D-glucose + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Citrate-Citric Acid</name>
      <ingredients>Citric acid + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Potassium Citrate-Sodium Citrate-Citric Acid</name>
      <ingredients>Citric acid + Potassium citrate + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Cytra 3</name>
      <ingredients>Citric acid + Potassium citrate + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>PramLyte</name>
      <ingredients>1,2-Docosahexanoyl-sn-glycero-3-phosphoserine + 1,2-icosapentoyl-sn-glycero-3-phosphoserine + Citric acid + Cobamamide + Cocarboxylase + Escitalopram + Ferrous cysteine glycinate + Flavin adenine dinucleotide + Folic acid + Glycine betaine + Leucovorin + Levomefolic acid + Magnesium ascorbate + NADH + Phosphatidyl serine + Pyridoxal phosphate + Sodium citrate + Zinc ascorbate</ingredients>
    </mixture>
    <mixture>
      <name>Balanced Salt</name>
      <ingredients>Calcium chloride + Magnesium chloride + Potassium chloride + Sodium acetate + Sodium chloride + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Balanced Salt</name>
      <ingredients>Calcium chloride + Magnesium chloride + Potassium chloride + Sodium acetate + Sodium chloride + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Potassium Citrate-Sodium Citrate-Citric Acid</name>
      <ingredients>Citric acid + Potassium citrate + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Citrate-Citric Acid</name>
      <ingredients>Citric acid + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Puralor</name>
      <ingredients>1-(c14-c18 esteroyl)-2-docosahexanoyl-sn-glycero-3-phosphocholine + 1-(c14-c18 esteroyl)-2-docosahexanoyl-sn-glycero-3-phosphoethanolamine + Acetylcysteine amide + Ascorbic acid + Cholecalciferol + Citric acid + Cobamamide + Egg phospholipids + Folic acid + Gastric intrinsic factor + L-threonic acid + Leucovorin + Levomefolic acid + Magnesium glycinate + Niacin + Pantethine + Papain + Riboflavin + Sodium citrate + Thiamine</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Citrate and Citric Acid</name>
      <ingredients>Citric acid + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Sterile Cord Blood Collection Unit (MSC128D)</name>
      <ingredients>Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Anticoagulant Citrate Dextrose A</name>
      <ingredients>Citric acid + D-glucose + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Oracit</name>
      <ingredients>Citric acid + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Citrate and Citric Acid</name>
      <ingredients>Citric acid + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Sterile Cord Blood Collection Unit (MSC127D)</name>
      <ingredients>Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Citrate 4% w/v Anticoagulant</name>
      <ingredients>Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Sterile Cord Blood Collection Unit</name>
      <ingredients>Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Nauzene</name>
      <ingredients>Dextrose, unspecified form + Fructose + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Nauzene Grape</name>
      <ingredients>D-glucose + Fructose + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Nauzene Grape</name>
      <ingredients>Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>InterSol</name>
      <ingredients>Sodium acetate + Sodium chloride + Sodium citrate + Sodium phosphate, dibasic, unspecified form + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Tricitrates</name>
      <ingredients>Citric acid + Potassium citrate + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Tricitrates</name>
      <ingredients>Citric acid + Potassium citrate + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>TERUFLEX Blood Bag System Anticoagulant Citrate Phosphate Dextrose Adenine (CPDA-1)</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Balanced Salt</name>
      <ingredients>Calcium chloride + Magnesium chloride + Potassium chloride + Sodium acetate + Sodium chloride + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>As 3</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Acd A</name>
      <ingredients>Citric acid + D-glucose + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Acd A</name>
      <ingredients>Citric acid + D-glucose + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Acd A</name>
      <ingredients>Citric acid + D-glucose + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Anticoagulant Citrate Dextrose A ACD-A</name>
      <ingredients>Citric acid + D-glucose + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Cpd/adsol</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Citrate and Citric Acid</name>
      <ingredients>Citric acid + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>IMUFLEX WB-SP BLOOD BAG SYSTEM with Integral Whole Blood Leukocyte Reduction Filter (Saving Platelets) with Diversion Blood Sampling Arm</name>
      <ingredients>Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic, unspecified form</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ACD Blood-Pack Units (PL 146 Plastic)</name>
      <ingredients>Citric acid + D-glucose + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Bss</name>
      <ingredients>Calcium chloride + Magnesium chloride + Potassium chloride + Sodium acetate + Sodium chloride + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Solucion InterSol</name>
      <ingredients>Sodium acetate + Sodium chloride + Sodium citrate + Sodium phosphate, dibasic, unspecified form + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>CPD/ADSOL Red Cell Preservation Solution System (PL 2209)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>CPD/ADSOL Red Cell Preservation Solution System (PL 2209)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Adsol Red Cell Preservation System In Plastic Container (pl 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Adsol Red Cell Preservation System In Plastic Container (pl 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpd/adsol</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Additive Formula 3</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Additive Formula 3</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Additive Formula 3</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Adsol Red Cell Preservation System In Plastic Container (pl 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Citrate Blood Pack Units, (PL 146 Plastic)</name>
      <ingredients>Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Citrate and Citric Acid</name>
      <ingredients>Citric acid + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Citrate and Citric Acid</name>
      <ingredients>Citric acid + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Nutricel Additive System - CP2D</name>
      <ingredients>Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Virtrate-3</name>
      <ingredients>Citric acid + Potassium citrate + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Virtrate-2</name>
      <ingredients>Citric acid + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Virtrate-2</name>
      <ingredients>Citric acid + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Virtrate-3</name>
      <ingredients>Citric acid + Potassium citrate + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>InterSol</name>
      <ingredients>Sodium acetate + Sodium chloride + Sodium citrate + Sodium phosphate, dibasic, unspecified form + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Adsol Red Cell Preservation System In Plastic Container (pl 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>EnLyte</name>
      <ingredients>1,2-Docosahexanoyl-sn-glycero-3-phosphoserine + 1,2-icosapentoyl-sn-glycero-3-phosphoserine + Citric acid + Cobamamide + Cocarboxylase + Ferrous cysteine glycinate + Flavin adenine dinucleotide + Folic acid + Glycine betaine + L-threonic acid + Leucovorin + Levomefolic acid + Magnesium ascorbate + NADH + Phosphatidyl serine + Pyridoxal phosphate + Sodium citrate + Zinc ascorbate</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Citrate and Citric Acid</name>
      <ingredients>Citric acid + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Leukotrap WB System</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>CPDA-1 Blood Collection System</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>CPDA-1 Blood Collection System</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>CVS Health Nausea Relief</name>
      <ingredients>Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Anticoagulant Citrate Phosphate Dextrose (CPD) Blood-Pack Units in PL 146 Plastic</name>
      <ingredients>Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Anticoagulant Citrate Phosphate Dextrose (CPD) Blood-Pack Units in PL 146 Plastic</name>
      <ingredients>Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Haemonetics Additive Solution Formula 3 (AS-3)</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Haemonetics Additive Solution Formula 3 (AS-3)</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Haemonetics Anticoagulant Citrate Phosphate Double Dextrose Solution (CP2D)</name>
      <ingredients>Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Anticoagulant Sodium Citrate</name>
      <ingredients>Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Bss</name>
      <ingredients>Calcium chloride + Magnesium chloride + Potassium chloride + Sodium acetate + Sodium chloride + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>triCitrasol</name>
      <ingredients>Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>CPD/ADSOL Red Cell Preservation Solution System (PL 2209)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Citrate Blood-Pack Units, (PL 146 Plastic)</name>
      <ingredients>Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpd/adsol</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpd</name>
      <ingredients>Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Acd-A</name>
      <ingredients>Citric acid + D-glucose + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Acd-A</name>
      <ingredients>Citric acid + D-glucose + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>MTL1 Leucoflex</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Nauzene</name>
      <ingredients>Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Citrate Blood-Pack Units, (PL 146 Plastic)</name>
      <ingredients>Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Citrate Blood-Pack Units, (PL 146 Plastic)</name>
      <ingredients>Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Leucoflex CGP</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Cpda-1</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>IMUFLEX WB-SP Blood Bag System with Integral Whole Blood Leukocyte Reduction Filter (Saving Platelets) with Diversion Blood Sampling Arm Anticoagulant Citrate Phosphate Dextrose (CPD) and OPTISOL (AS-5) Red Cell Preservative</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic, unspecified form</ingredients>
    </mixture>
    <mixture>
      <name>TERUFLEX Blood Bag System with Blood Sampling Arm Anticoagulant Citrate Phosphate Dextrose (CPD) AND OPTISOL (AS-5) Red Cell Preservative</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic, unspecified form</ingredients>
    </mixture>
    <mixture>
      <name>Haemonetics Anticoagulant Sodium Citrate</name>
      <ingredients>Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Haemonetics Anticoagulant Citrate Dextrose Solution</name>
      <ingredients>Citric acid + D-glucose + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>IMUFLEX WB-RP Blood Bag System with Integral Whole Blood Leukocyte Reduction Filter (Removing Platelets) with Diversion Blood Sampling Arm Anticoagulant Citrate Phosphate Dextrose (CPD) AND OPTISOL (AS-5) Red Cell Preservative</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic, unspecified form</ingredients>
    </mixture>
    <mixture>
      <name>Leukotrap WB System</name>
      <ingredients>Adenine + Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>TERUFLEX Blood Bag System with Diversion Blood Sampling Arm Anticoagulant Citrate Phosphate Dextrose (CPD) AND OPTISOL (AS-5) Red Cell Preservative</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic, unspecified form</ingredients>
    </mixture>
    <mixture>
      <name>TERUFLEX Blood Bag System Anticoagulant Citrate Phosphate Dextrose (CPD) AND OPTISOL Red Cell Preservative</name>
      <ingredients>Adenine + Citric acid + D-glucose + D-glucose + Mannitol + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic, unspecified form</ingredients>
    </mixture>
    <mixture>
      <name>Anticoagulant Sod Citrate Soltn 4gm/100ml</name>
      <ingredients>Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Microlax Micro Enema</name>
      <ingredients>Sodium citrate + Sodium lauryl sulfoacetate + Sorbitol</ingredients>
    </mixture>
    <mixture>
      <name>Bss Sterile Irrigating Solution</name>
      <ingredients>Calcium chloride + Magnesium chloride + Potassium chloride + Sodium acetate + Sodium chloride + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Additive Solution Formula 3 As-3</name>
      <ingredients>Adenine + Citric acid + Dextrose, unspecified form + Sodium chloride + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Lytren Rhs Liq</name>
      <ingredients>Citric acid + Potassium citrate + Sodium chloride + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Anticoagulant Citrate Dextrose Solution USP (acd) Formula B</name>
      <ingredients>Citric acid + Dextrose, unspecified form + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Metrate</name>
      <ingredients>Dextromethorphan + Diphenylpyraline + Potassium Iodide + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Citrocarbonate Eff Pws</name>
      <ingredients>Citric acid + Sodium bicarbonate + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Microlax Micro-enema</name>
      <ingredients>Sodium citrate + Sodium lauryl sulfoacetate + Sorbitol</ingredients>
    </mixture>
    <mixture>
      <name>A-C-D Solution</name>
      <ingredients>Citric acid + Dextrose, unspecified form + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Mercodol With Decapryn</name>
      <ingredients>Doxylamine + Etafedrine + Hydrocodone + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Blood Pack Unit Cpd</name>
      <ingredients>Citric acid + Dextrose, unspecified form + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Vito Bronches Sirop</name>
      <ingredients>Dextromethorphan + Diphenylpyraline + Potassium Iodide + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Neo Tuss Syr</name>
      <ingredients>Chlorpheniramine + Dextromethorphan + Guaifenesin + Phenylephrine + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Bronchodex Fort-DM Syr</name>
      <ingredients>Ammonium chloride + Dextromethorphan + Levomenthol + Mepyramine + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Bromo Seltzer</name>
      <ingredients>Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Lemon Eno 2650mg/pck</name>
      <ingredients>Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Orange Eno 2645mg/pck</name>
      <ingredients>Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Cpd Adenine Cpda 1</name>
      <ingredients>Adenine + Citric acid + Dextrose, unspecified form + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Lytren</name>
      <ingredients>Citric acid + Dextrose, unspecified form + Potassium citrate + Sodium chloride + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Balanced Salt Solution</name>
      <ingredients>Calcium chloride + Magnesium chloride + Potassium chloride + Sodium acetate + Sodium chloride + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Oracit</name>
      <ingredients>Citric acid + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Anticoagulant Sodium Citrate Sol 4% USP</name>
      <ingredients>Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Anticoagulant Citrate Dextr Sol Formula A USP</name>
      <ingredients>Citric acid + Dextrose, unspecified form + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Rehydralyte</name>
      <ingredients>Dextrose, unspecified form + Potassium citrate + Sodium chloride + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Iocare Balanced Salt Solution</name>
      <ingredients>Calcium chloride + Magnesium chloride + Potassium chloride + Sodium acetate + Sodium chloride + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Cpd Solution</name>
      <ingredients>Citric acid + D-glucose + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Anticoagulant Solution Citrate Phosphate Dextrose (cpd)</name>
      <ingredients>Citric acid + Dextrose, unspecified form + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Ratio-calmydone</name>
      <ingredients>Doxylamine + Etafedrine + Hydrocodone + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Odan Balanced Salt Solution</name>
      <ingredients>Calcium chloride + Magnesium chloride + Potassium chloride + Sodium acetate + Sodium chloride + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Anticoagulant Cit Phos Dex Adenine Sol USP</name>
      <ingredients>Adenine + Citric acid + Dextrose, unspecified form + Sodium citrate + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Anticoagulant Sodium Citrate Solution USP</name>
      <ingredients>Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Dalmacol</name>
      <ingredients>Doxylamine + Etafedrine + Ethanol + Hydrocodone + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Dalmacol</name>
      <ingredients>Doxylamine + Etafedrine + Ethanol + Hydrocodone + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Balanced Salt Solution</name>
      <ingredients>Calcium chloride + Magnesium chloride + Potassium chloride + Sodium acetate + Sodium chloride + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Anticoagulant Citrate Dextrose Solution USP (acd) Formula A</name>
      <ingredients>Citric acid + Dextrose, unspecified form + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Anticoagulant Citrate Dextrose Solution USP (acd) Formula A</name>
      <ingredients>Citric acid + Dextrose, unspecified form + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Amo Endosol Solution</name>
      <ingredients>Calcium chloride + Magnesium chloride + Potassium chloride + Sodium acetate + Sodium chloride + Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Anticoagulant Sodium Citrate 4% W/V Solution, USP</name>
      <ingredients>Sodium citrate</ingredients>
    </mixture>
    <mixture>
      <name>Ssp+</name>
      <ingredients>Magnesium chloride + Potassium chloride + Sodium acetate + Sodium chloride + Sodium citrate + Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Ssp+</name>
      <ingredients>Magnesium chloride + Potassium chloride + Sodium acetate + Sodium chloride + Sodium citrate + Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Acids, Acyclic</category>
      <mesh-id>D000144</mesh-id>
    </category>
    <category>
      <category>Antacids and Adsorbents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Anticoagulants</category>
      <mesh-id>D000925</mesh-id>
    </category>
    <category>
      <category>Blood and Blood Forming Organs</category>
      <mesh-id/>
    </category>
    <category>
      <category>Blood Substitutes and Perfusion Solutions</category>
      <mesh-id/>
    </category>
    <category>
      <category>Buffers</category>
      <mesh-id>D002021</mesh-id>
    </category>
    <category>
      <category>Calculi Dissolution Agent</category>
      <mesh-id/>
    </category>
    <category>
      <category>Citrates</category>
      <mesh-id>D002951</mesh-id>
    </category>
    <category>
      <category>Citric Acid Derivatives</category>
      <mesh-id/>
    </category>
    <category>
      <category>Compounds used in a research, industrial, or household setting</category>
      <mesh-id>D020313</mesh-id>
    </category>
    <category>
      <category>Diet, Food, and Nutrition</category>
      <mesh-id>D000066888</mesh-id>
    </category>
    <category>
      <category>Food</category>
      <mesh-id>D005502</mesh-id>
    </category>
    <category>
      <category>Food Additives</category>
      <mesh-id>D005503</mesh-id>
    </category>
    <category>
      <category>Food and Beverages</category>
      <mesh-id>D019602</mesh-id>
    </category>
    <category>
      <category>Food Ingredients</category>
      <mesh-id>D000074385</mesh-id>
    </category>
    <category>
      <category>Food Preservatives</category>
      <mesh-id>D005520</mesh-id>
    </category>
    <category>
      <category>Hematologic Agents</category>
      <mesh-id>D006401</mesh-id>
    </category>
    <category>
      <category>Irrigating Solutions</category>
      <mesh-id/>
    </category>
    <category>
      <category>Laboratory Chemicals</category>
      <mesh-id>D019995</mesh-id>
    </category>
    <category>
      <category>Miscellaneous Anticoagulants</category>
      <mesh-id/>
    </category>
    <category>
      <category>Miscellaneous GI Drugs</category>
      <mesh-id/>
    </category>
    <category>
      <category>Neurotoxic agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Physiological Phenomena</category>
      <mesh-id>D010829</mesh-id>
    </category>
    <category>
      <category>Salt Solutions</category>
      <mesh-id/>
    </category>
    <category>
      <category>Tricarboxylic Acids</category>
      <mesh-id>D014233</mesh-id>
    </category>
    <category>
      <category>Urinary Alkalinisers</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form>Liquid</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Unknown</route>
      <strength/>
    </dosage>
    <dosage>
      <form/>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intraocular</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Extracorporeal</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Extracorporeal</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Unknown</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Extracorporeal</route>
      <strength>40 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>10 g/250mL</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Ophthalmic</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder</form>
      <route>Oral</route>
      <strength>3.5 g</strength>
    </dosage>
    <dosage>
      <form>Granule, effervescent</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet, chewable</form>
      <route>Oral</route>
      <strength>230 mg/1</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Irrigation</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Syrup</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Capsule, delayed release pellets</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intraocular</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Enema; liquid</form>
      <route>Rectal</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Rectal</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Syrup</form>
      <route>Oral</route>
      <strength>0.921 g/15mL</strength>
    </dosage>
    <dosage>
      <form>Powder</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet, chewable</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>10.0 g/250mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>4 g/100mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>4 g/100mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>2 g/50mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Extracorporeal</route>
      <strength>14 g/30mL</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="B05CB02">
      <level code="B05CB">Salt solutions</level>
      <level code="B05C">IRRIGATING SOLUTIONS</level>
      <level code="B05">BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS</level>
      <level code="B">BLOOD AND BLOOD FORMING ORGANS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>20:12.04.92</ahfs-code>
    <ahfs-code>56:04.00</ahfs-code>
    <ahfs-code>56:92.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB09154.pdf?1496339791</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB09154.pdf?1496339061</msds>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB06605</drugbank-id>
      <name>Apixaban</name>
      <description>Apixaban may increase the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06695</drugbank-id>
      <name>Dabigatran etexilate</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01254</drugbank-id>
      <name>Dasatinib</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01609</drugbank-id>
      <name>Deferasirox</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Sodium citrate is combined with Deferasirox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01586</drugbank-id>
      <name>Ursodeoxycholic acid</name>
      <description>The risk or severity of bleeding and bruising can be increased when Sodium citrate is combined with Ursodeoxycholic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02123</drugbank-id>
      <name>Glycochenodeoxycholic Acid</name>
      <description>The risk or severity of bleeding and bruising can be increased when Sodium citrate is combined with Glycochenodeoxycholic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02659</drugbank-id>
      <name>Cholic Acid</name>
      <description>The risk or severity of bleeding and bruising can be increased when Sodium citrate is combined with Cholic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02691</drugbank-id>
      <name>Glycocholic acid</name>
      <description>The risk or severity of bleeding and bruising can be increased when Sodium citrate is combined with Glycocholic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03619</drugbank-id>
      <name>Deoxycholic acid</name>
      <description>The risk or severity of bleeding and bruising can be increased when Sodium citrate is combined with Deoxycholic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04348</drugbank-id>
      <name>Taurocholic acid</name>
      <description>The risk or severity of bleeding and bruising can be increased when Sodium citrate is combined with Taurocholic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05990</drugbank-id>
      <name>Obeticholic acid</name>
      <description>The risk or severity of bleeding and bruising can be increased when Sodium citrate is combined with Obeticholic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06777</drugbank-id>
      <name>Chenodeoxycholic acid</name>
      <description>The risk or severity of bleeding and bruising can be increased when Sodium citrate is combined with Chenodeoxycholic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08833</drugbank-id>
      <name>Taurochenodeoxycholic acid</name>
      <description>The risk or severity of bleeding and bruising can be increased when Sodium citrate is combined with Taurochenodeoxycholic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08834</drugbank-id>
      <name>Tauroursodeoxycholic acid</name>
      <description>The risk or severity of bleeding and bruising can be increased when Sodium citrate is combined with Tauroursodeoxycholic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08857</drugbank-id>
      <name>Bamet-UD2</name>
      <description>The risk or severity of bleeding and bruising can be increased when Sodium citrate is combined with Bamet-UD2.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11622</drugbank-id>
      <name>Dehydrocholic acid</name>
      <description>The risk or severity of bleeding and bruising can be increased when Sodium citrate is combined with Dehydrocholic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11789</drugbank-id>
      <name>Hyodeoxycholic Acid</name>
      <description>The risk or severity of bleeding and bruising can be increased when Sodium citrate is combined with Hyodeoxycholic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09075</drugbank-id>
      <name>Edoxaban</name>
      <description>The risk or severity of bleeding can be increased when Edoxaban is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09053</drugbank-id>
      <name>Ibrutinib</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08935</drugbank-id>
      <name>Obinutuzumab</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Sodium citrate is combined with Obinutuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06228</drugbank-id>
      <name>Rivaroxaban</name>
      <description>Sodium citrate may increase the anticoagulant activities of Rivaroxaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06206</drugbank-id>
      <name>Sugammadex</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Sodium citrate is combined with Sugammadex.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09070</drugbank-id>
      <name>Tibolone</name>
      <description>Tibolone may increase the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00932</drugbank-id>
      <name>Tipranavir</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00013</drugbank-id>
      <name>Urokinase</name>
      <description>Urokinase may increase the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00163</drugbank-id>
      <name>Vitamin E</name>
      <description>Vitamin E may increase the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09030</drugbank-id>
      <name>Vorapaxar</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01381</drugbank-id>
      <name>Ginkgo biloba</name>
      <description>The therapeutic efficacy of Sodium citrate can be increased when used in combination with Ginkgo biloba.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01181</drugbank-id>
      <name>Ifosfamide</name>
      <description>The risk or severity of bleeding can be increased when Ifosfamide is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00468</drugbank-id>
      <name>Quinine</name>
      <description>The therapeutic efficacy of Sodium citrate can be increased when used in combination with Quinine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>The therapeutic efficacy of Sodium citrate can be increased when used in combination with Quinidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00675</drugbank-id>
      <name>Tamoxifen</name>
      <description>The risk or severity of bleeding can be increased when Tamoxifen is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00539</drugbank-id>
      <name>Toremifene</name>
      <description>The risk or severity of bleeding can be increased when Toremifene is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06723</drugbank-id>
      <name>Aluminum hydroxide</name>
      <description>Sodium citrate can cause an increase in the absorption of Aluminum hydroxide resulting in an increased serum concentration and potentially a worsening of adverse effects.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00686</drugbank-id>
      <name>Pentosan polysulfate</name>
      <description>Pentosan polysulfate may increase the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00583</drugbank-id>
      <name>Levocarnitine</name>
      <description>The therapeutic efficacy of Sodium citrate can be increased when used in combination with Levocarnitine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00255</drugbank-id>
      <name>Diethylstilbestrol</name>
      <description>Diethylstilbestrol may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00269</drugbank-id>
      <name>Chlorotrianisene</name>
      <description>Chlorotrianisene may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00286</drugbank-id>
      <name>Conjugated estrogens</name>
      <description>Conjugated estrogens may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00783</drugbank-id>
      <name>Estradiol</name>
      <description>Estradiol may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00977</drugbank-id>
      <name>Ethinylestradiol</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01357</drugbank-id>
      <name>Mestranol</name>
      <description>Mestranol may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04573</drugbank-id>
      <name>Estriol</name>
      <description>Estriol may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04574</drugbank-id>
      <name>Estrone sulfate</name>
      <description>Estrone sulfate may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04575</drugbank-id>
      <name>Quinestrol</name>
      <description>Quinestrol may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07931</drugbank-id>
      <name>Hexestrol</name>
      <description>Hexestrol may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09317</drugbank-id>
      <name>Synthetic Conjugated Estrogens, A</name>
      <description>Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09318</drugbank-id>
      <name>Synthetic Conjugated Estrogens, B</name>
      <description>Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09369</drugbank-id>
      <name>Polyestradiol phosphate</name>
      <description>Polyestradiol phosphate may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09381</drugbank-id>
      <name>Esterified estrogens</name>
      <description>Esterified estrogens may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11478</drugbank-id>
      <name>Zeranol</name>
      <description>Zeranol may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11674</drugbank-id>
      <name>Equol</name>
      <description>Equol may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12487</drugbank-id>
      <name>Promestriene</name>
      <description>Promestriene may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13143</drugbank-id>
      <name>Methallenestril</name>
      <description>Methallenestril may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13386</drugbank-id>
      <name>Epimestrol</name>
      <description>Epimestrol may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13418</drugbank-id>
      <name>Moxestrol</name>
      <description>Moxestrol may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13952</drugbank-id>
      <name>Estradiol acetate</name>
      <description>Estradiol acetate may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13953</drugbank-id>
      <name>Estradiol benzoate</name>
      <description>Estradiol benzoate may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13954</drugbank-id>
      <name>Estradiol cypionate</name>
      <description>Estradiol cypionate may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13956</drugbank-id>
      <name>Estradiol valerate</name>
      <description>Estradiol valerate may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15334</drugbank-id>
      <name>Biochanin A</name>
      <description>Biochanin A may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15335</drugbank-id>
      <name>Formononetin</name>
      <description>Formononetin may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09211</drugbank-id>
      <name>Limaprost</name>
      <description>The risk or severity of adverse effects can be increased when Limaprost is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00159</drugbank-id>
      <name>Icosapent</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00244</drugbank-id>
      <name>Mesalazine</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00328</drugbank-id>
      <name>Indomethacin</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00461</drugbank-id>
      <name>Nabumetone</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00465</drugbank-id>
      <name>Ketorolac</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00469</drugbank-id>
      <name>Tenoxicam</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00482</drugbank-id>
      <name>Celecoxib</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00500</drugbank-id>
      <name>Tolmetin</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00533</drugbank-id>
      <name>Rofecoxib</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00554</drugbank-id>
      <name>Piroxicam</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00573</drugbank-id>
      <name>Fenoprofen</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00580</drugbank-id>
      <name>Valdecoxib</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00586</drugbank-id>
      <name>Diclofenac</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00605</drugbank-id>
      <name>Sulindac</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00712</drugbank-id>
      <name>Flurbiprofen</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00749</drugbank-id>
      <name>Etodolac</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00784</drugbank-id>
      <name>Mefenamic acid</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00788</drugbank-id>
      <name>Naproxen</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00795</drugbank-id>
      <name>Sulfasalazine</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00812</drugbank-id>
      <name>Phenylbutazone</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00814</drugbank-id>
      <name>Meloxicam</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00821</drugbank-id>
      <name>Carprofen</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00861</drugbank-id>
      <name>Diflunisal</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00936</drugbank-id>
      <name>Salicylic acid</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00939</drugbank-id>
      <name>Meclofenamic acid</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00991</drugbank-id>
      <name>Oxaprozin</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01009</drugbank-id>
      <name>Ketoprofen</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01014</drugbank-id>
      <name>Balsalazide</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01250</drugbank-id>
      <name>Olsalazine</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Olsalazine is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01283</drugbank-id>
      <name>Lumiracoxib</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01397</drugbank-id>
      <name>Magnesium salicylate</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01399</drugbank-id>
      <name>Salsalate</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01401</drugbank-id>
      <name>Choline magnesium trisalicylate</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01419</drugbank-id>
      <name>Antrafenine</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01424</drugbank-id>
      <name>Aminophenazone</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01435</drugbank-id>
      <name>Antipyrine</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01600</drugbank-id>
      <name>Tiaprofenic acid</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01628</drugbank-id>
      <name>Etoricoxib</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02224</drugbank-id>
      <name>Taxifolin</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03585</drugbank-id>
      <name>Oxyphenbutazone</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04552</drugbank-id>
      <name>Niflumic acid</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Niflumic acid is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04725</drugbank-id>
      <name>Licofelone</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04812</drugbank-id>
      <name>Benoxaprofen</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Benoxaprofen is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04817</drugbank-id>
      <name>Metamizole</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Metamizole is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04828</drugbank-id>
      <name>Zomepirac</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Zomepirac is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05095</drugbank-id>
      <name>Cimicoxib</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Cimicoxib is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06725</drugbank-id>
      <name>Lornoxicam</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Lornoxicam is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06736</drugbank-id>
      <name>Aceclofenac</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06737</drugbank-id>
      <name>Zaltoprofen</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Zaltoprofen is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07402</drugbank-id>
      <name>Azapropazone</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07477</drugbank-id>
      <name>Felbinac</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Felbinac is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08439</drugbank-id>
      <name>Parecoxib</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Parecoxib is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08797</drugbank-id>
      <name>Salicylamide</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Salicylamide is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08940</drugbank-id>
      <name>Kebuzone</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Kebuzone is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08942</drugbank-id>
      <name>Isoxicam</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Isoxicam is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08951</drugbank-id>
      <name>Indoprofen</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Indoprofen is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08955</drugbank-id>
      <name>Ibuproxam</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Ibuproxam is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08976</drugbank-id>
      <name>Floctafenine</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Floctafenine is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08981</drugbank-id>
      <name>Fenbufen</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Fenbufen is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08984</drugbank-id>
      <name>Etofenamate</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Etofenamate is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08991</drugbank-id>
      <name>Epirizole</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Epirizole is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09084</drugbank-id>
      <name>Benzydamine</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Benzydamine is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09212</drugbank-id>
      <name>Loxoprofen</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Loxoprofen is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09214</drugbank-id>
      <name>Dexketoprofen</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Dexketoprofen is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09215</drugbank-id>
      <name>Droxicam</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Droxicam is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09216</drugbank-id>
      <name>Tolfenamic acid</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Tolfenamic acid is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09217</drugbank-id>
      <name>Firocoxib</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Firocoxib is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09218</drugbank-id>
      <name>Clonixin</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Clonixin is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09285</drugbank-id>
      <name>Morniflumate</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Morniflumate is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09288</drugbank-id>
      <name>Propacetamol</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Propacetamol is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09295</drugbank-id>
      <name>Talniflumate</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Talniflumate is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11455</drugbank-id>
      <name>Robenacoxib</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Robenacoxib is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11466</drugbank-id>
      <name>Tepoxalin</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Tepoxalin is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11518</drugbank-id>
      <name>Flunixin</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Flunixin is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12399</drugbank-id>
      <name>Polmacoxib</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Polmacoxib is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12480</drugbank-id>
      <name>Betulinic Acid</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Betulinic Acid is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12610</drugbank-id>
      <name>Ebselen</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Ebselen is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13001</drugbank-id>
      <name>Tinoridine</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Tinoridine is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13167</drugbank-id>
      <name>Alclofenac</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Alclofenac is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13217</drugbank-id>
      <name>Fentiazac</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Fentiazac is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13232</drugbank-id>
      <name>Suxibuzone</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Suxibuzone is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13286</drugbank-id>
      <name>Bumadizone</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Bumadizone is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13314</drugbank-id>
      <name>Alminoprofen</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Alminoprofen is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13317</drugbank-id>
      <name>Flunoxaprofen</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Flunoxaprofen is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13364</drugbank-id>
      <name>Feprazone</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Feprazone is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13371</drugbank-id>
      <name>Difenpiramide</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Difenpiramide is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13407</drugbank-id>
      <name>Nifenazone</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Nifenazone is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13432</drugbank-id>
      <name>Lonazolac</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Lonazolac is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13481</drugbank-id>
      <name>Tenidap</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Tenidap is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13501</drugbank-id>
      <name>Bendazac</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Bendazac is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13514</drugbank-id>
      <name>Pranoprofen</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Pranoprofen is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13524</drugbank-id>
      <name>Propyphenazone</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Propyphenazone is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13527</drugbank-id>
      <name>Proglumetacin</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Proglumetacin is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13538</drugbank-id>
      <name>Guacetisal</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Guacetisal is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13544</drugbank-id>
      <name>Ethenzamide</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Ethenzamide is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13612</drugbank-id>
      <name>Carbaspirin calcium</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Carbaspirin calcium is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13629</drugbank-id>
      <name>Mofebutazone</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Mofebutazone is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13649</drugbank-id>
      <name>Proquazone</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Proquazone is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13657</drugbank-id>
      <name>Benorilate</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Benorilate is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13722</drugbank-id>
      <name>Pirprofen</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Pirprofen is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13860</drugbank-id>
      <name>Imidazole salicylate</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Imidazole salicylate is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14059</drugbank-id>
      <name>SC-236</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when SC-236 is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14060</drugbank-id>
      <name>NS-398</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when NS-398 is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14938</drugbank-id>
      <name>Flurbiprofen axetil</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen axetil is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04865</drugbank-id>
      <name>Omacetaxine mepesuccinate</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Omacetaxine mepesuccinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11133</drugbank-id>
      <name>Omega-3 fatty acids</name>
      <description>Omega-3 fatty acids may increase the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00081</drugbank-id>
      <name>Tositumomab</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Sodium citrate is combined with Tositumomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00048</drugbank-id>
      <name>Collagenase clostridium histolyticum</name>
      <description>The risk or severity of adverse effects can be increased when Sodium citrate is combined with Collagenase clostridium histolyticum.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00389</drugbank-id>
      <name>Carbimazole</name>
      <description>Carbimazole may increase the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00550</drugbank-id>
      <name>Propylthiouracil</name>
      <description>Propylthiouracil may increase the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00763</drugbank-id>
      <name>Methimazole</name>
      <description>Methimazole may increase the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03374</drugbank-id>
      <name>3,5-Diiodotyrosine</name>
      <description>3,5-Diiodotyrosine may increase the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07637</drugbank-id>
      <name>Dibromotyrosine</name>
      <description>Dibromotyrosine may increase the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09418</drugbank-id>
      <name>Potassium perchlorate</name>
      <description>Potassium perchlorate may increase the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13644</drugbank-id>
      <name>Methylthiouracil</name>
      <description>Methylthiouracil may increase the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13804</drugbank-id>
      <name>Benzylthiouracil</name>
      <description>Benzylthiouracil may increase the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00834</drugbank-id>
      <name>Mifepristone</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Mifepristone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01115</drugbank-id>
      <name>Nifedipine</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Nifedipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04066</drugbank-id>
      <name>para-Coumaric Acid</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with para-Coumaric Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04682</drugbank-id>
      <name>Octylphenoxy polyethoxyethanol</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Octylphenoxy polyethoxyethanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05830</drugbank-id>
      <name>Trestolone</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Trestolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06266</drugbank-id>
      <name>Lonidamine</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Lonidamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08867</drugbank-id>
      <name>Ulipristal</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Ulipristal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09401</drugbank-id>
      <name>Isosorbide</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Isosorbide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11507</drugbank-id>
      <name>Cloprostenol</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Cloprostenol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12025</drugbank-id>
      <name>Triptolide</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Triptolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13044</drugbank-id>
      <name>Gossypol</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Gossypol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13310</drugbank-id>
      <name>Ormeloxifene</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Ormeloxifene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00294</drugbank-id>
      <name>Etonogestrel</name>
      <description>Etonogestrel may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00304</drugbank-id>
      <name>Desogestrel</name>
      <description>Desogestrel may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00351</drugbank-id>
      <name>Megestrol acetate</name>
      <description>Megestrol acetate may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00367</drugbank-id>
      <name>Levonorgestrel</name>
      <description>Levonorgestrel may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00378</drugbank-id>
      <name>Dydrogesterone</name>
      <description>Dydrogesterone may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00396</drugbank-id>
      <name>Progesterone</name>
      <description>Progesterone may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00603</drugbank-id>
      <name>Medroxyprogesterone acetate</name>
      <description>Medroxyprogesterone acetate may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00717</drugbank-id>
      <name>Norethisterone</name>
      <description>Norethisterone may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00823</drugbank-id>
      <name>Ethynodiol diacetate</name>
      <description>Ethynodiol diacetate may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00957</drugbank-id>
      <name>Norgestimate</name>
      <description>Norgestimate may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01395</drugbank-id>
      <name>Drospirenone</name>
      <description>Drospirenone may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01431</drugbank-id>
      <name>Allylestrenol</name>
      <description>Allylestrenol may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04839</drugbank-id>
      <name>Cyproterone acetate</name>
      <description>Cyproterone acetate may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06713</drugbank-id>
      <name>Norelgestromin</name>
      <description>Norelgestromin may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06730</drugbank-id>
      <name>Gestodene</name>
      <description>Gestodene may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06789</drugbank-id>
      <name>Hydroxyprogesterone caproate</name>
      <description>Hydroxyprogesterone caproate may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09123</drugbank-id>
      <name>Dienogest</name>
      <description>Dienogest may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09124</drugbank-id>
      <name>Medrogestone</name>
      <description>Medrogestone may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09371</drugbank-id>
      <name>Norethynodrel</name>
      <description>Norethynodrel may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09389</drugbank-id>
      <name>Norgestrel</name>
      <description>Norgestrel may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11372</drugbank-id>
      <name>Altrenogest</name>
      <description>Altrenogest may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11619</drugbank-id>
      <name>Gestrinone</name>
      <description>Gestrinone may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11636</drugbank-id>
      <name>Nomegestrol</name>
      <description>Nomegestrol may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12474</drugbank-id>
      <name>Lynestrenol</name>
      <description>Lynestrenol may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13230</drugbank-id>
      <name>Gestonorone</name>
      <description>Gestonorone may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13528</drugbank-id>
      <name>Chlormadinone</name>
      <description>Chlormadinone may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13533</drugbank-id>
      <name>Methylestrenolone</name>
      <description>Methylestrenolone may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13563</drugbank-id>
      <name>Norgestrienone</name>
      <description>Norgestrienone may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13602</drugbank-id>
      <name>Promegestone</name>
      <description>Promegestone may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13685</drugbank-id>
      <name>Quingestanol</name>
      <description>Quingestanol may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13857</drugbank-id>
      <name>Demegestone</name>
      <description>Demegestone may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13866</drugbank-id>
      <name>Etynodiol</name>
      <description>Etynodiol may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13981</drugbank-id>
      <name>Nomegestrol acetate</name>
      <description>Nomegestrol acetate may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14570</drugbank-id>
      <name>Hydroxyprogesterone</name>
      <description>Hydroxyprogesterone may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14678</drugbank-id>
      <name>Norethindrone enanthate</name>
      <description>Norethindrone enanthate may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14679</drugbank-id>
      <name>Quingestanol acetate</name>
      <description>Quingestanol acetate may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00233</drugbank-id>
      <name>Aminosalicylic acid</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01294</drugbank-id>
      <name>Bismuth subsalicylate</name>
      <description>The risk or severity of bleeding can be increased when Bismuth subsalicylate is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06251</drugbank-id>
      <name>Dersalazine</name>
      <description>The risk or severity of bleeding can be increased when Dersalazine is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06807</drugbank-id>
      <name>Phenyl aminosalicylate</name>
      <description>The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09543</drugbank-id>
      <name>Methyl salicylate</name>
      <description>The risk or severity of bleeding can be increased when Methyl salicylate is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11079</drugbank-id>
      <name>Trolamine salicylate</name>
      <description>The risk or severity of bleeding can be increased when Trolamine salicylate is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13509</drugbank-id>
      <name>Aloxiprin</name>
      <description>The risk or severity of bleeding can be increased when Aloxiprin is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14006</drugbank-id>
      <name>Choline salicylate</name>
      <description>The risk or severity of bleeding can be increased when Choline salicylate is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14026</drugbank-id>
      <name>Thiosalicylic acid</name>
      <description>The risk or severity of bleeding can be increased when Thiosalicylic acid is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00054</drugbank-id>
      <name>Abciximab</name>
      <description>The risk or severity of bleeding can be increased when Abciximab is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00063</drugbank-id>
      <name>Eptifibatide</name>
      <description>The risk or severity of bleeding can be increased when Eptifibatide is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00208</drugbank-id>
      <name>Ticlopidine</name>
      <description>The risk or severity of bleeding can be increased when Ticlopidine is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00261</drugbank-id>
      <name>Anagrelide</name>
      <description>The risk or severity of bleeding can be increased when Anagrelide is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00758</drugbank-id>
      <name>Clopidogrel</name>
      <description>The risk or severity of bleeding can be increased when Clopidogrel is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00775</drugbank-id>
      <name>Tirofiban</name>
      <description>The risk or severity of bleeding can be increased when Tirofiban is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00975</drugbank-id>
      <name>Dipyridamole</name>
      <description>The risk or severity of bleeding can be increased when Dipyridamole is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01088</drugbank-id>
      <name>Iloprost</name>
      <description>The risk or severity of bleeding can be increased when Iloprost is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01138</drugbank-id>
      <name>Sulfinpyrazone</name>
      <description>The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01166</drugbank-id>
      <name>Cilostazol</name>
      <description>The risk or severity of bleeding can be increased when Cilostazol is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01207</drugbank-id>
      <name>Ridogrel</name>
      <description>The risk or severity of bleeding can be increased when Ridogrel is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01236</drugbank-id>
      <name>Sevoflurane</name>
      <description>The risk or severity of bleeding can be increased when Sevoflurane is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01240</drugbank-id>
      <name>Epoprostenol</name>
      <description>The risk or severity of bleeding can be increased when Epoprostenol is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02709</drugbank-id>
      <name>Resveratrol</name>
      <description>The risk or severity of bleeding can be increased when Resveratrol is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04743</drugbank-id>
      <name>Nimesulide</name>
      <description>The risk or severity of bleeding can be increased when Nimesulide is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04905</drugbank-id>
      <name>Tesmilifene</name>
      <description>The risk or severity of bleeding can be increased when Tesmilifene is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04932</drugbank-id>
      <name>Defibrotide</name>
      <description>The risk or severity of bleeding can be increased when Defibrotide is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05229</drugbank-id>
      <name>Beraprost</name>
      <description>The risk or severity of bleeding can be increased when Beraprost is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05266</drugbank-id>
      <name>Ibudilast</name>
      <description>The risk or severity of bleeding can be increased when Ibudilast is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05767</drugbank-id>
      <name>Andrographolide</name>
      <description>The risk or severity of bleeding can be increased when Andrographolide is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06081</drugbank-id>
      <name>Caplacizumab</name>
      <description>The risk or severity of bleeding can be increased when Caplacizumab is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06209</drugbank-id>
      <name>Prasugrel</name>
      <description>The risk or severity of bleeding can be increased when Prasugrel is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06441</drugbank-id>
      <name>Cangrelor</name>
      <description>The risk or severity of bleeding can be increased when Cangrelor is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07615</drugbank-id>
      <name>Tranilast</name>
      <description>The risk or severity of bleeding can be increased when Tranilast is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08814</drugbank-id>
      <name>Triflusal</name>
      <description>The risk or severity of bleeding can be increased when Triflusal is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08816</drugbank-id>
      <name>Ticagrelor</name>
      <description>The risk or severity of bleeding can be increased when Ticagrelor is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08887</drugbank-id>
      <name>Icosapent ethyl</name>
      <description>The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09283</drugbank-id>
      <name>Trapidil</name>
      <description>The risk or severity of bleeding can be increased when Trapidil is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12092</drugbank-id>
      <name>Naftopidil</name>
      <description>The risk or severity of bleeding can be increased when Naftopidil is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12163</drugbank-id>
      <name>Sarpogrelate</name>
      <description>The risk or severity of bleeding can be increased when Sarpogrelate is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12321</drugbank-id>
      <name>Ifetroban</name>
      <description>The risk or severity of bleeding can be increased when Ifetroban is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12445</drugbank-id>
      <name>Nitroaspirin</name>
      <description>The risk or severity of bleeding can be increased when Nitroaspirin is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12465</drugbank-id>
      <name>Ketanserin</name>
      <description>The risk or severity of bleeding can be increased when Ketanserin is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12545</drugbank-id>
      <name>Indobufen</name>
      <description>The risk or severity of bleeding can be increased when Indobufen is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12749</drugbank-id>
      <name>Butylphthalide</name>
      <description>The risk or severity of bleeding can be increased when Butylphthalide is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12771</drugbank-id>
      <name>Hydroxytyrosol</name>
      <description>The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13036</drugbank-id>
      <name>Ramatroban</name>
      <description>The risk or severity of bleeding can be increased when Ramatroban is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13327</drugbank-id>
      <name>Picotamide</name>
      <description>The risk or severity of bleeding can be increased when Picotamide is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13367</drugbank-id>
      <name>Cloricromen</name>
      <description>The risk or severity of bleeding can be increased when Cloricromen is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13400</drugbank-id>
      <name>Linsidomine</name>
      <description>The risk or severity of bleeding can be increased when Linsidomine is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13510</drugbank-id>
      <name>Buflomedil</name>
      <description>The risk or severity of bleeding can be increased when Buflomedil is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13929</drugbank-id>
      <name>Relcovaptan</name>
      <description>The risk or severity of bleeding can be increased when Relcovaptan is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00374</drugbank-id>
      <name>Treprostinil</name>
      <description>The risk or severity of bleeding can be increased when Treprostinil is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00078</drugbank-id>
      <name>Ibritumomab tiuxetan</name>
      <description>The risk or severity of adverse effects can be increased when Sodium citrate is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03404</drugbank-id>
      <name>Hemin</name>
      <description>Hemin may increase the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13783</drugbank-id>
      <name>Acemetacin</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Acemetacin is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00624</drugbank-id>
      <name>Testosterone</name>
      <description>Testosterone may increase the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01420</drugbank-id>
      <name>Testosterone propionate</name>
      <description>Testosterone propionate may increase the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01481</drugbank-id>
      <name>1-Testosterone</name>
      <description>1-Testosterone may increase the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01485</drugbank-id>
      <name>4-Hydroxytestosterone</name>
      <description>4-Hydroxytestosterone may increase the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01510</drugbank-id>
      <name>Dehydrochloromethyltestosterone</name>
      <description>Dehydrochloromethyltestosterone may increase the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01541</drugbank-id>
      <name>Boldenone</name>
      <description>Boldenone may increase the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01543</drugbank-id>
      <name>18-methyl-19-nortestosterone</name>
      <description>18-methyl-19-nortestosterone may increase the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01564</drugbank-id>
      <name>Calusterone</name>
      <description>Calusterone may increase the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01569</drugbank-id>
      <name>Formebolone</name>
      <description>Formebolone may increase the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01572</drugbank-id>
      <name>Methyl-1-testosterone</name>
      <description>Methyl-1-testosterone may increase the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02901</drugbank-id>
      <name>Stanolone</name>
      <description>Stanolone may increase the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07447</drugbank-id>
      <name>5beta-dihydrotestosterone</name>
      <description>5beta-dihydrotestosterone may increase the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08619</drugbank-id>
      <name>Testosterone succinate</name>
      <description>Testosterone succinate may increase the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11429</drugbank-id>
      <name>Mibolerone</name>
      <description>Mibolerone may increase the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13943</drugbank-id>
      <name>Testosterone cypionate</name>
      <description>Testosterone cypionate may increase the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13944</drugbank-id>
      <name>Testosterone enanthate</name>
      <description>Testosterone enanthate may increase the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13946</drugbank-id>
      <name>Testosterone undecanoate</name>
      <description>Testosterone undecanoate may increase the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13947</drugbank-id>
      <name>Testosterone enantate benzilic acid hydrazone</name>
      <description>Testosterone enantate benzilic acid hydrazone may increase the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13951</drugbank-id>
      <name>Stanolone acetate</name>
      <description>Stanolone acetate may increase the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13958</drugbank-id>
      <name>Trestolone acetate</name>
      <description>Trestolone acetate may increase the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14093</drugbank-id>
      <name>(1,2,6,7-3H)Testosterone</name>
      <description>(1,2,6,7-3H)Testosterone may increase the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14655</drugbank-id>
      <name>Drostanolone propionate</name>
      <description>Drostanolone propionate may increase the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11051</drugbank-id>
      <name>Azficel-T</name>
      <description>The risk or severity of adverse effects can be increased when Sodium citrate is combined with Azficel-T.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09568</drugbank-id>
      <name>Omega-3-carboxylic acids</name>
      <description>The therapeutic efficacy of Sodium citrate can be increased when used in combination with Omega-3-carboxylic acids.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00025</drugbank-id>
      <name>Antihemophilic factor, human recombinant</name>
      <description>The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00036</drugbank-id>
      <name>Coagulation factor VIIa Recombinant Human</name>
      <description>The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00100</drugbank-id>
      <name>Coagulation Factor IX (Recombinant)</name>
      <description>The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00258</drugbank-id>
      <name>Calcium acetate</name>
      <description>The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01373</drugbank-id>
      <name>Calcium</name>
      <description>The therapeutic efficacy of Calcium can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01783</drugbank-id>
      <name>Pantothenic acid</name>
      <description>The therapeutic efficacy of Pantothenic acid can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01942</drugbank-id>
      <name>Formic acid</name>
      <description>The therapeutic efficacy of Formic acid can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02261</drugbank-id>
      <name>Platelet Activating Factor</name>
      <description>The therapeutic efficacy of Platelet Activating Factor can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06724</drugbank-id>
      <name>Calcium carbonate</name>
      <description>The therapeutic efficacy of Calcium carbonate can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09109</drugbank-id>
      <name>Turoctocog alfa</name>
      <description>The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09222</drugbank-id>
      <name>Fibrinogen human</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09310</drugbank-id>
      <name>Catridecacog</name>
      <description>The therapeutic efficacy of Catridecacog can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09329</drugbank-id>
      <name>Antihemophilic Factor (Recombinant), PEGylated</name>
      <description>The therapeutic efficacy of Antihemophilic Factor (Recombinant), PEGylated can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11093</drugbank-id>
      <name>Calcium Citrate</name>
      <description>The therapeutic efficacy of Calcium Citrate can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11126</drugbank-id>
      <name>Calcium gluconate</name>
      <description>The therapeutic efficacy of Calcium gluconate can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11168</drugbank-id>
      <name>Calcium threonate</name>
      <description>The therapeutic efficacy of Calcium threonate can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11311</drugbank-id>
      <name>Prothrombin</name>
      <description>The therapeutic efficacy of Prothrombin can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11330</drugbank-id>
      <name>Factor IX Complex (Human)</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11348</drugbank-id>
      <name>Calcium Phosphate</name>
      <description>The therapeutic efficacy of Calcium Phosphate can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11606</drugbank-id>
      <name>Susoctocog alfa</name>
      <description>The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11608</drugbank-id>
      <name>Eftrenonacog alfa</name>
      <description>The therapeutic efficacy of Eftrenonacog alfa can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11668</drugbank-id>
      <name>Rusalatide acetate</name>
      <description>The therapeutic efficacy of Rusalatide acetate can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12409</drugbank-id>
      <name>Vatreptacog alfa</name>
      <description>The therapeutic efficacy of Vatreptacog alfa can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12909</drugbank-id>
      <name>Factor XIII (human)</name>
      <description>The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13133</drugbank-id>
      <name>Von Willebrand Factor Human</name>
      <description>The therapeutic efficacy of Von Willebrand Factor Human can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13148</drugbank-id>
      <name>Coagulation factor X human</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13150</drugbank-id>
      <name>Coagulation factor VII human</name>
      <description>The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13151</drugbank-id>
      <name>Anti-inhibitor coagulant complex</name>
      <description>The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13152</drugbank-id>
      <name>Coagulation Factor IX Human</name>
      <description>The therapeutic efficacy of Coagulation Factor IX Human can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13192</drugbank-id>
      <name>Antihemophilic factor human</name>
      <description>The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13197</drugbank-id>
      <name>Kallidinogenase</name>
      <description>The therapeutic efficacy of Kallidinogenase can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13201</drugbank-id>
      <name>Trenonacog alfa</name>
      <description>The therapeutic efficacy of Trenonacog alfa can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13884</drugbank-id>
      <name>Albutrepenonacog alfa</name>
      <description>The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13923</drugbank-id>
      <name>Emicizumab</name>
      <description>The therapeutic efficacy of Emicizumab can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13933</drugbank-id>
      <name>Nonacog beta pegol</name>
      <description>The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13999</drugbank-id>
      <name>Moroctocog alfa</name>
      <description>The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14473</drugbank-id>
      <name>Beroctocog alfa</name>
      <description>The therapeutic efficacy of Beroctocog alfa can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14562</drugbank-id>
      <name>Andexanet alfa</name>
      <description>The therapeutic efficacy of Andexanet alfa can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14577</drugbank-id>
      <name>Calcium cation</name>
      <description>The therapeutic efficacy of Calcium cation can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14700</drugbank-id>
      <name>Damoctocog alfa pegol</name>
      <description>The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14738</drugbank-id>
      <name>Turoctocog alfa pegol</name>
      <description>The therapeutic efficacy of Turoctocog alfa pegol can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00176</drugbank-id>
      <name>Fluvoxamine</name>
      <description>The risk or severity of hemorrhage can be increased when Fluvoxamine is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00215</drugbank-id>
      <name>Citalopram</name>
      <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00472</drugbank-id>
      <name>Fluoxetine</name>
      <description>The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01149</drugbank-id>
      <name>Nefazodone</name>
      <description>The risk or severity of hemorrhage can be increased when Nefazodone is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04832</drugbank-id>
      <name>Zimelidine</name>
      <description>The risk or severity of hemorrhage can be increased when Zimelidine is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04884</drugbank-id>
      <name>Dapoxetine</name>
      <description>The risk or severity of hemorrhage can be increased when Dapoxetine is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06731</drugbank-id>
      <name>Seproxetine</name>
      <description>The risk or severity of hemorrhage can be increased when Seproxetine is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08953</drugbank-id>
      <name>Indalpine</name>
      <description>The risk or severity of hemorrhage can be increased when Indalpine is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12693</drugbank-id>
      <name>Ritanserin</name>
      <description>The risk or severity of hemorrhage can be increased when Ritanserin is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13233</drugbank-id>
      <name>Alaproclate</name>
      <description>The risk or severity of hemorrhage can be increased when Alaproclate is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00476</drugbank-id>
      <name>Duloxetine</name>
      <description>The risk or severity of hemorrhage can be increased when Duloxetine is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01105</drugbank-id>
      <name>Sibutramine</name>
      <description>The risk or severity of hemorrhage can be increased when Sibutramine is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04896</drugbank-id>
      <name>Milnacipran</name>
      <description>The risk or severity of hemorrhage can be increased when Milnacipran is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06700</drugbank-id>
      <name>Desvenlafaxine</name>
      <description>The risk or severity of hemorrhage can be increased when Desvenlafaxine is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08918</drugbank-id>
      <name>Levomilnacipran</name>
      <description>The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00715</drugbank-id>
      <name>Paroxetine</name>
      <description>The risk or severity of hemorrhage can be increased when Paroxetine is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00285</drugbank-id>
      <name>Venlafaxine</name>
      <description>Venlafaxine may increase the antiplatelet activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00601</drugbank-id>
      <name>Linezolid</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Linezolid is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00614</drugbank-id>
      <name>Furazolidone</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Furazolidone is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00721</drugbank-id>
      <name>Procaine</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Procaine is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00752</drugbank-id>
      <name>Tranylcypromine</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00780</drugbank-id>
      <name>Phenelzine</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Phenelzine is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00805</drugbank-id>
      <name>Minaprine</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Minaprine is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01037</drugbank-id>
      <name>Selegiline</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Selegiline is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01168</drugbank-id>
      <name>Procarbazine</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01171</drugbank-id>
      <name>Moclobemide</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Moclobemide is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01247</drugbank-id>
      <name>Isocarboxazid</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Isocarboxazid is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01367</drugbank-id>
      <name>Rasagiline</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01626</drugbank-id>
      <name>Pargyline</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Pargyline is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04017</drugbank-id>
      <name>Clorgiline</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Clorgiline is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04818</drugbank-id>
      <name>Iproniazid</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Iproniazid is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04820</drugbank-id>
      <name>Nialamide</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Nialamide is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06654</drugbank-id>
      <name>Safinamide</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Safinamide is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08550</drugbank-id>
      <name>7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09241</drugbank-id>
      <name>Methylene blue</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Methylene blue is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09243</drugbank-id>
      <name>Hydracarbazine</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Hydracarbazine is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09244</drugbank-id>
      <name>Pirlindole</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Pirlindole is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09245</drugbank-id>
      <name>Toloxatone</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Toloxatone is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09246</drugbank-id>
      <name>Benmoxin</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Benmoxin is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09248</drugbank-id>
      <name>Mebanazine</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Mebanazine is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09249</drugbank-id>
      <name>Octamoxin</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Octamoxin is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09250</drugbank-id>
      <name>Pheniprazine</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Pheniprazine is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09251</drugbank-id>
      <name>Phenoxypropazine</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Phenoxypropazine is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09252</drugbank-id>
      <name>Pivhydrazine</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Pivhydrazine is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09253</drugbank-id>
      <name>Safrazine</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Safrazine is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09254</drugbank-id>
      <name>Caroxazone</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Caroxazone is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13875</drugbank-id>
      <name>Harmaline</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Harmaline is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13876</drugbank-id>
      <name>Brofaromine</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Brofaromine is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00006</drugbank-id>
      <name>Bivalirudin</name>
      <description>The risk or severity of bleeding can be increased when Bivalirudin is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00266</drugbank-id>
      <name>Dicoumarol</name>
      <description>The risk or severity of bleeding can be increased when Dicoumarol is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00278</drugbank-id>
      <name>Argatroban</name>
      <description>The risk or severity of bleeding can be increased when Argatroban is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00407</drugbank-id>
      <name>Ardeparin</name>
      <description>The risk or severity of bleeding can be increased when Ardeparin is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00498</drugbank-id>
      <name>Phenindione</name>
      <description>The risk or severity of bleeding can be increased when Phenindione is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00569</drugbank-id>
      <name>Fondaparinux</name>
      <description>The risk or severity of bleeding can be increased when Fondaparinux is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>The risk or severity of bleeding can be increased when Warfarin is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00946</drugbank-id>
      <name>Phenprocoumon</name>
      <description>The risk or severity of bleeding can be increased when Phenprocoumon is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00974</drugbank-id>
      <name>Edetic acid</name>
      <description>The risk or severity of bleeding can be increased when Edetic acid is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01109</drugbank-id>
      <name>Heparin</name>
      <description>The risk or severity of bleeding can be increased when Heparin is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01225</drugbank-id>
      <name>Enoxaparin</name>
      <description>The risk or severity of bleeding can be increased when Enoxaparin is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>The risk or severity of bleeding can be increased when Acenocoumarol is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04898</drugbank-id>
      <name>Ximelagatran</name>
      <description>The risk or severity of bleeding can be increased when Ximelagatran is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05099</drugbank-id>
      <name>Ancrod</name>
      <description>The risk or severity of bleeding can be increased when Ancrod is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06271</drugbank-id>
      <name>Sulodexide</name>
      <description>The risk or severity of bleeding can be increased when Sulodexide is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06406</drugbank-id>
      <name>Idraparinux</name>
      <description>The risk or severity of bleeding can be increased when Idraparinux is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06635</drugbank-id>
      <name>Otamixaban</name>
      <description>The risk or severity of bleeding can be increased when Otamixaban is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06754</drugbank-id>
      <name>Danaparoid</name>
      <description>The risk or severity of bleeding can be increased when Danaparoid is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06779</drugbank-id>
      <name>Dalteparin</name>
      <description>The risk or severity of bleeding can be increased when Dalteparin is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07767</drugbank-id>
      <name>Ferulic acid</name>
      <description>The risk or severity of bleeding can be increased when Ferulic acid is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08794</drugbank-id>
      <name>Ethyl biscoumacetate</name>
      <description>The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08813</drugbank-id>
      <name>Nadroparin</name>
      <description>The risk or severity of bleeding can be increased when Nadroparin is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09255</drugbank-id>
      <name>Dextran</name>
      <description>The risk or severity of bleeding can be increased when Dextran is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09259</drugbank-id>
      <name>Reviparin</name>
      <description>The risk or severity of bleeding can be increased when Reviparin is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09261</drugbank-id>
      <name>Certoparin</name>
      <description>The risk or severity of bleeding can be increased when Certoparin is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11095</drugbank-id>
      <name>Desirudin</name>
      <description>The risk or severity of bleeding can be increased when Desirudin is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11268</drugbank-id>
      <name>Protocatechualdehyde</name>
      <description>The risk or severity of bleeding can be increased when Protocatechualdehyde is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11312</drugbank-id>
      <name>Protein C</name>
      <description>The risk or severity of bleeding can be increased when Protein C is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11598</drugbank-id>
      <name>Antithrombin III human</name>
      <description>The risk or severity of bleeding can be increased when Antithrombin III human is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11984</drugbank-id>
      <name>Letaxaban</name>
      <description>The risk or severity of bleeding can be increased when Letaxaban is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12289</drugbank-id>
      <name>Darexaban</name>
      <description>The risk or severity of bleeding can be increased when Darexaban is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12598</drugbank-id>
      <name>Nafamostat</name>
      <description>The risk or severity of bleeding can be increased when Nafamostat is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12831</drugbank-id>
      <name>Gabexate</name>
      <description>The risk or severity of bleeding can be increased when Gabexate is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13124</drugbank-id>
      <name>Troxerutin</name>
      <description>The risk or severity of bleeding can be increased when Troxerutin is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13136</drugbank-id>
      <name>Fluindione</name>
      <description>The risk or severity of bleeding can be increased when Fluindione is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13149</drugbank-id>
      <name>Protein S human</name>
      <description>The risk or severity of bleeding can be increased when Protein S human is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13616</drugbank-id>
      <name>Melagatran</name>
      <description>The risk or severity of bleeding can be increased when Melagatran is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00031</drugbank-id>
      <name>Tenecteplase</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00055</drugbank-id>
      <name>Drotrecogin alfa</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Drotrecogin alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06822</drugbank-id>
      <name>Tinzaparin</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Tinzaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13199</drugbank-id>
      <name>Brinase</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Brinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13646</drugbank-id>
      <name>Saruplase</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Saruplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00086</drugbank-id>
      <name>Streptokinase</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Streptokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04925</drugbank-id>
      <name>Desmoteplase</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Desmoteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05254</drugbank-id>
      <name>Fibrinolysin</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Fibrinolysin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06543</drugbank-id>
      <name>Astaxanthin</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Astaxanthin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08994</drugbank-id>
      <name>Ditazole</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Ditazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09258</drugbank-id>
      <name>Bemiparin</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Bemiparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09260</drugbank-id>
      <name>Parnaparin</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Parnaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13275</drugbank-id>
      <name>Clorindione</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Clorindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13347</drugbank-id>
      <name>Diphenadione</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Diphenadione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13451</drugbank-id>
      <name>Tioclomarol</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Tioclomarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00001</drugbank-id>
      <name>Lepirudin</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00009</drugbank-id>
      <name>Alteplase</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00015</drugbank-id>
      <name>Reteplase</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00029</drugbank-id>
      <name>Anistreplase</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14094</drugbank-id>
      <name>Tocopherylquinone</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Tocopherylquinone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06679</drugbank-id>
      <name>Amediplase</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Amediplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03410</drugbank-id>
      <name>4-hydroxycoumarin</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with 4-hydroxycoumarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08496</drugbank-id>
      <name>(R)-warfarin</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with (R)-warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14055</drugbank-id>
      <name>(S)-Warfarin</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with (S)-Warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12364</drugbank-id>
      <name>Betrixaban</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Betrixaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14598</drugbank-id>
      <name>Edetate calcium disodium anhydrous</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Edetate calcium disodium anhydrous.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11154</drugbank-id>
      <name>Zinc citrate</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Zinc citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14600</drugbank-id>
      <name>Edetate disodium anhydrous</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Edetate disodium anhydrous.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11166</drugbank-id>
      <name>Antithrombin Alfa</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Antithrombin Alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04665</drugbank-id>
      <name>Coumarin</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Coumarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14726</drugbank-id>
      <name>Dabigatran</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Dabigatran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06294</drugbank-id>
      <name>Semuloparin</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Semuloparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12726</drugbank-id>
      <name>Monteplase</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Monteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00203</drugbank-id>
      <name>Sildenafil</name>
      <description>The risk or severity of hemorrhage can be increased when Sodium citrate is combined with Sildenafil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00008</drugbank-id>
      <name>Peginterferon alfa-2a</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Peginterferon alfa-2a.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00011</drugbank-id>
      <name>Interferon alfa-n1</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Interferon alfa-n1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00018</drugbank-id>
      <name>Interferon alfa-n3</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Interferon alfa-n3.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00022</drugbank-id>
      <name>Peginterferon alfa-2b</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00033</drugbank-id>
      <name>Interferon gamma-1b</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Interferon gamma-1b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00034</drugbank-id>
      <name>Interferon alfa-2a, Recombinant</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Interferon alfa-2a, Recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00041</drugbank-id>
      <name>Aldesleukin</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00056</drugbank-id>
      <name>Gemtuzumab ozogamicin</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Gemtuzumab ozogamicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00068</drugbank-id>
      <name>Interferon beta-1b</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Interferon beta-1b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00069</drugbank-id>
      <name>Interferon alfacon-1</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Interferon alfacon-1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00073</drugbank-id>
      <name>Rituximab</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Rituximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00087</drugbank-id>
      <name>Alemtuzumab</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Alemtuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00105</drugbank-id>
      <name>Interferon alfa-2b</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Interferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00112</drugbank-id>
      <name>Bevacizumab</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Bevacizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00120</drugbank-id>
      <name>Phenylalanine</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Phenylalanine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00188</drugbank-id>
      <name>Bortezomib</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Bortezomib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00242</drugbank-id>
      <name>Cladribine</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00262</drugbank-id>
      <name>Carmustine</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Carmustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00276</drugbank-id>
      <name>Amsacrine</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Amsacrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00291</drugbank-id>
      <name>Chlorambucil</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Chlorambucil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00293</drugbank-id>
      <name>Raltitrexed</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Raltitrexed.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00305</drugbank-id>
      <name>Mitomycin</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Mitomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00307</drugbank-id>
      <name>Bexarotene</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Bexarotene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00309</drugbank-id>
      <name>Vindesine</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Vindesine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00322</drugbank-id>
      <name>Floxuridine</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Floxuridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00352</drugbank-id>
      <name>Tioguanine</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Tioguanine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00361</drugbank-id>
      <name>Vinorelbine</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Vinorelbine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00380</drugbank-id>
      <name>Dexrazoxane</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Dexrazoxane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00398</drugbank-id>
      <name>Sorafenib</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Sorafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00428</drugbank-id>
      <name>Streptozocin</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Streptozocin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00441</drugbank-id>
      <name>Gemcitabine</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Gemcitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00444</drugbank-id>
      <name>Teniposide</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Teniposide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00445</drugbank-id>
      <name>Epirubicin</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Epirubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00446</drugbank-id>
      <name>Chloramphenicol</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Chloramphenicol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00480</drugbank-id>
      <name>Lenalidomide</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Lenalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00488</drugbank-id>
      <name>Altretamine</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Altretamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00495</drugbank-id>
      <name>Zidovudine</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Zidovudine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00515</drugbank-id>
      <name>Cisplatin</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Cisplatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00526</drugbank-id>
      <name>Oxaliplatin</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Oxaliplatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00531</drugbank-id>
      <name>Cyclophosphamide</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Cyclophosphamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00544</drugbank-id>
      <name>Fluorouracil</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00552</drugbank-id>
      <name>Pentostatin</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Pentostatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00563</drugbank-id>
      <name>Methotrexate</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Methotrexate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00564</drugbank-id>
      <name>Carbamazepine</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Carbamazepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00570</drugbank-id>
      <name>Vinblastine</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Vinblastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00619</drugbank-id>
      <name>Imatinib</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Imatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00631</drugbank-id>
      <name>Clofarabine</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Clofarabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00642</drugbank-id>
      <name>Pemetrexed</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Pemetrexed.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00694</drugbank-id>
      <name>Daunorubicin</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Daunorubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00762</drugbank-id>
      <name>Irinotecan</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Irinotecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00773</drugbank-id>
      <name>Etoposide</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Etoposide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00851</drugbank-id>
      <name>Dacarbazine</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Dacarbazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00853</drugbank-id>
      <name>Temozolomide</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Temozolomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00859</drugbank-id>
      <name>Penicillamine</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Penicillamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00864</drugbank-id>
      <name>Tacrolimus</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Tacrolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00877</drugbank-id>
      <name>Sirolimus</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Sirolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00888</drugbank-id>
      <name>Mechlorethamine</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Mechlorethamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00928</drugbank-id>
      <name>Azacitidine</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Azacitidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00958</drugbank-id>
      <name>Carboplatin</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Carboplatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00970</drugbank-id>
      <name>Dactinomycin</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Dactinomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00987</drugbank-id>
      <name>Cytarabine</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Cytarabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00997</drugbank-id>
      <name>Doxorubicin</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Doxorubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01005</drugbank-id>
      <name>Hydroxyurea</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Hydroxyurea.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01008</drugbank-id>
      <name>Busulfan</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Busulfan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01030</drugbank-id>
      <name>Topotecan</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Topotecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01033</drugbank-id>
      <name>Mercaptopurine</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Mercaptopurine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01041</drugbank-id>
      <name>Thalidomide</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Thalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01042</drugbank-id>
      <name>Melphalan</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Melphalan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01073</drugbank-id>
      <name>Fludarabine</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Fludarabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01099</drugbank-id>
      <name>Flucytosine</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Flucytosine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01101</drugbank-id>
      <name>Capecitabine</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Capecitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01169</drugbank-id>
      <name>Arsenic trioxide</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Arsenic trioxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01177</drugbank-id>
      <name>Idarubicin</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Idarubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01204</drugbank-id>
      <name>Mitoxantrone</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Mitoxantrone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01206</drugbank-id>
      <name>Lomustine</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Lomustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01229</drugbank-id>
      <name>Paclitaxel</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Paclitaxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01248</drugbank-id>
      <name>Docetaxel</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Docetaxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01262</drugbank-id>
      <name>Decitabine</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Decitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01280</drugbank-id>
      <name>Nelarabine</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Nelarabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01590</drugbank-id>
      <name>Everolimus</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Everolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02546</drugbank-id>
      <name>Vorinostat</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Vorinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04572</drugbank-id>
      <name>Thiotepa</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Thiotepa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04845</drugbank-id>
      <name>Ixabepilone</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Ixabepilone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04868</drugbank-id>
      <name>Nilotinib</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Nilotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05015</drugbank-id>
      <name>Belinostat</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Belinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05109</drugbank-id>
      <name>Trabectedin</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Trabectedin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05258</drugbank-id>
      <name>Interferon alfa</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Interferon alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05472</drugbank-id>
      <name>omega interferon</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with omega interferon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05773</drugbank-id>
      <name>Trastuzumab emtansine</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Trastuzumab emtansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06287</drugbank-id>
      <name>Temsirolimus</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Temsirolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06616</drugbank-id>
      <name>Bosutinib</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Bosutinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06769</drugbank-id>
      <name>Bendamustine</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Bendamustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06772</drugbank-id>
      <name>Cabazitaxel</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Cabazitaxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08871</drugbank-id>
      <name>Eribulin</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Eribulin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08877</drugbank-id>
      <name>Ruxolitinib</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Ruxolitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08889</drugbank-id>
      <name>Carfilzomib</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Carfilzomib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08895</drugbank-id>
      <name>Tofacitinib</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Tofacitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08901</drugbank-id>
      <name>Ponatinib</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Ponatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08910</drugbank-id>
      <name>Pomalidomide</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Pomalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09042</drugbank-id>
      <name>Tedizolid phosphate</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Tedizolid phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09052</drugbank-id>
      <name>Blinatumomab</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Blinatumomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09073</drugbank-id>
      <name>Palbociclib</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Palbociclib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09074</drugbank-id>
      <name>Olaparib</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Olaparib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09077</drugbank-id>
      <name>Dinutuximab</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Dinutuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09122</drugbank-id>
      <name>Peginterferon beta-1a</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Peginterferon beta-1a.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12814</drugbank-id>
      <name>Cepeginterferon alfa-2B</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Cepeginterferon alfa-2B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00182</drugbank-id>
      <name>Amphetamine</name>
      <description>The excretion of Amphetamine can be decreased when combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00191</drugbank-id>
      <name>Phentermine</name>
      <description>The excretion of Phentermine can be decreased when combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00852</drugbank-id>
      <name>Pseudoephedrine</name>
      <description>The excretion of Pseudoephedrine can be decreased when combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00865</drugbank-id>
      <name>Benzphetamine</name>
      <description>The excretion of Benzphetamine can be decreased when combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00937</drugbank-id>
      <name>Diethylpropion</name>
      <description>The excretion of Diethylpropion can be decreased when combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01255</drugbank-id>
      <name>Lisdexamfetamine</name>
      <description>The excretion of Lisdexamfetamine can be decreased when combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01365</drugbank-id>
      <name>Mephentermine</name>
      <description>The excretion of Mephentermine can be decreased when combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01442</drugbank-id>
      <name>MMDA</name>
      <description>The excretion of MMDA can be decreased when combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01454</drugbank-id>
      <name>Midomafetamine</name>
      <description>The excretion of Midomafetamine can be decreased when combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01467</drugbank-id>
      <name>2,5-Dimethoxy-4-ethylamphetamine</name>
      <description>The excretion of 2,5-Dimethoxy-4-ethylamphetamine can be decreased when combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01484</drugbank-id>
      <name>4-Bromo-2,5-dimethoxyamphetamine</name>
      <description>The excretion of 4-Bromo-2,5-dimethoxyamphetamine can be decreased when combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01509</drugbank-id>
      <name>Tenamfetamine</name>
      <description>The excretion of Tenamfetamine can be decreased when combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01556</drugbank-id>
      <name>Chlorphentermine</name>
      <description>The excretion of Chlorphentermine can be decreased when combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01566</drugbank-id>
      <name>Methylenedioxyethamphetamine</name>
      <description>The excretion of Methylenedioxyethamphetamine can be decreased when combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01576</drugbank-id>
      <name>Dextroamphetamine</name>
      <description>The excretion of Dextroamphetamine can be decreased when combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01577</drugbank-id>
      <name>Metamfetamine</name>
      <description>The excretion of Metamfetamine can be decreased when combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09480</drugbank-id>
      <name>Iofetamine I-123</name>
      <description>The excretion of Iofetamine I-123 can be decreased when combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12080</drugbank-id>
      <name>Ritobegron</name>
      <description>The excretion of Ritobegron can be decreased when combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13108</drugbank-id>
      <name>Mephedrone</name>
      <description>The excretion of Mephedrone can be decreased when combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13624</drugbank-id>
      <name>Methoxyphenamine</name>
      <description>The excretion of Methoxyphenamine can be decreased when combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13703</drugbank-id>
      <name>Gepefrine</name>
      <description>The excretion of Gepefrine can be decreased when combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13940</drugbank-id>
      <name>2,5-Dimethoxy-4-ethylthioamphetamine</name>
      <description>The excretion of 2,5-Dimethoxy-4-ethylthioamphetamine can be decreased when combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00256</drugbank-id>
      <name>Lymecycline</name>
      <description>The therapeutic efficacy of Lymecycline can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00453</drugbank-id>
      <name>Clomocycline</name>
      <description>The therapeutic efficacy of Clomocycline can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00560</drugbank-id>
      <name>Tigecycline</name>
      <description>The therapeutic efficacy of Tigecycline can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00595</drugbank-id>
      <name>Oxytetracycline</name>
      <description>The therapeutic efficacy of Oxytetracycline can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00618</drugbank-id>
      <name>Demeclocycline</name>
      <description>The therapeutic efficacy of Demeclocycline can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00759</drugbank-id>
      <name>Tetracycline</name>
      <description>The therapeutic efficacy of Tetracycline can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00931</drugbank-id>
      <name>Metacycline</name>
      <description>The therapeutic efficacy of Metacycline can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01017</drugbank-id>
      <name>Minocycline</name>
      <description>The therapeutic efficacy of Minocycline can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01301</drugbank-id>
      <name>Rolitetracycline</name>
      <description>The therapeutic efficacy of Rolitetracycline can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12035</drugbank-id>
      <name>Sarecycline</name>
      <description>The therapeutic efficacy of Sarecycline can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12329</drugbank-id>
      <name>Eravacycline</name>
      <description>The therapeutic efficacy of Eravacycline can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12455</drugbank-id>
      <name>Omadacycline</name>
      <description>The therapeutic efficacy of Omadacycline can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13092</drugbank-id>
      <name>Meclocycline</name>
      <description>The therapeutic efficacy of Meclocycline can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13264</drugbank-id>
      <name>Penimepicycline</name>
      <description>The therapeutic efficacy of Penimepicycline can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00229</drugbank-id>
      <name>Cefotiam</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Cefotiam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00267</drugbank-id>
      <name>Cefmenoxime</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Cefmenoxime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00274</drugbank-id>
      <name>Cefmetazole</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Cefmetazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00430</drugbank-id>
      <name>Cefpiramide</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Cefpiramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00438</drugbank-id>
      <name>Ceftazidime</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00447</drugbank-id>
      <name>Loracarbef</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Loracarbef.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00456</drugbank-id>
      <name>Cefalotin</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Cefalotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00493</drugbank-id>
      <name>Cefotaxime</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Cefotaxime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00535</drugbank-id>
      <name>Cefdinir</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Cefdinir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00567</drugbank-id>
      <name>Cephalexin</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Cephalexin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00671</drugbank-id>
      <name>Cefixime</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Cefixime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00689</drugbank-id>
      <name>Cephaloglycin</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Cephaloglycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00833</drugbank-id>
      <name>Cefaclor</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Cefaclor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00923</drugbank-id>
      <name>Ceforanide</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Ceforanide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01066</drugbank-id>
      <name>Cefditoren</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Cefditoren.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01112</drugbank-id>
      <name>Cefuroxime</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Cefuroxime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01139</drugbank-id>
      <name>Cefapirin</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Cefapirin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01140</drugbank-id>
      <name>Cefadroxil</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Cefadroxil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01150</drugbank-id>
      <name>Cefprozil</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Cefprozil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01212</drugbank-id>
      <name>Ceftriaxone</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Ceftriaxone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01326</drugbank-id>
      <name>Cefamandole</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Cefamandole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01327</drugbank-id>
      <name>Cefazolin</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Cefazolin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01328</drugbank-id>
      <name>Cefonicid</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Cefonicid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01329</drugbank-id>
      <name>Cefoperazone</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Cefoperazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01330</drugbank-id>
      <name>Cefotetan</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Cefotetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01331</drugbank-id>
      <name>Cefoxitin</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Cefoxitin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01332</drugbank-id>
      <name>Ceftizoxime</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Ceftizoxime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01333</drugbank-id>
      <name>Cefradine</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Cefradine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01413</drugbank-id>
      <name>Cefepime</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Cefepime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01414</drugbank-id>
      <name>Cefacetrile</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Cefacetrile.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01415</drugbank-id>
      <name>Ceftibuten</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Ceftibuten.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01416</drugbank-id>
      <name>Cefpodoxime</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Cefpodoxime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04570</drugbank-id>
      <name>Latamoxef</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Latamoxef.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04918</drugbank-id>
      <name>Ceftobiprole</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Ceftobiprole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06590</drugbank-id>
      <name>Ceftaroline fosamil</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Ceftaroline fosamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09008</drugbank-id>
      <name>Cefaloridine</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Cefaloridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09050</drugbank-id>
      <name>Ceftolozane</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Ceftolozane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09062</drugbank-id>
      <name>Cefminox</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Cefminox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11367</drugbank-id>
      <name>Cefroxadine</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Cefroxadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11935</drugbank-id>
      <name>Flomoxef</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Flomoxef.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13266</drugbank-id>
      <name>Cefatrizine</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Cefatrizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13461</drugbank-id>
      <name>Cefcapene</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Cefcapene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13470</drugbank-id>
      <name>Cefodizime</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Cefodizime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13499</drugbank-id>
      <name>Cefsulodin</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Cefsulodin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13504</drugbank-id>
      <name>Cefetamet</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Cefetamet.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13638</drugbank-id>
      <name>Cefbuperazone</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Cefbuperazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13667</drugbank-id>
      <name>Cefozopran</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Cefozopran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13682</drugbank-id>
      <name>Cefpirome</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Cefpirome.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13778</drugbank-id>
      <name>Cefazedone</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Cefazedone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13821</drugbank-id>
      <name>Ceftezole</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Ceftezole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14725</drugbank-id>
      <name>Cefamandole nafate</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Cefamandole nafate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00254</drugbank-id>
      <name>Doxycycline</name>
      <description>The risk or severity of bleeding can be increased when Doxycycline is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00207</drugbank-id>
      <name>Azithromycin</name>
      <description>The risk or severity of adverse effects can be increased when Azithromycin is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09539</drugbank-id>
      <name>Omega-3-acid ethyl esters</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01043</drugbank-id>
      <name>Memantine</name>
      <description>The excretion of Memantine can be decreased when combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>Acetylsalicylic acid may increase the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01606</drugbank-id>
      <name>Tazobactam</name>
      <description>The risk or severity of bleeding can be increased when Tazobactam is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00199</drugbank-id>
      <name>Erythromycin</name>
      <description>The risk or severity of bleeding can be increased when Erythromycin is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00656</drugbank-id>
      <name>Trazodone</name>
      <description>The risk or severity of bleeding can be increased when Trazodone is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00620</drugbank-id>
      <name>Triamcinolone</name>
      <description>The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Triamcinolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09079</drugbank-id>
      <name>Nintedanib</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Nintedanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01175</drugbank-id>
      <name>Escitalopram</name>
      <description>The risk or severity of bleeding can be increased when Escitalopram is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01104</drugbank-id>
      <name>Sertraline</name>
      <description>The risk or severity of bleeding can be increased when Sertraline is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00806</drugbank-id>
      <name>Pentoxifylline</name>
      <description>The therapeutic efficacy of Sodium citrate can be increased when used in combination with Pentoxifylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>Cyclosporine may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00202</drugbank-id>
      <name>Succinylcholine</name>
      <description>Succinylcholine may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00206</drugbank-id>
      <name>Reserpine</name>
      <description>Reserpine may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00260</drugbank-id>
      <name>Cycloserine</name>
      <description>Cycloserine may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00344</drugbank-id>
      <name>Protriptyline</name>
      <description>Protriptyline may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00372</drugbank-id>
      <name>Thiethylperazine</name>
      <description>Thiethylperazine may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00391</drugbank-id>
      <name>Sulpiride</name>
      <description>Sulpiride may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00408</drugbank-id>
      <name>Loxapine</name>
      <description>Loxapine may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00409</drugbank-id>
      <name>Remoxipride</name>
      <description>Remoxipride may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00433</drugbank-id>
      <name>Prochlorperazine</name>
      <description>Prochlorperazine may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00450</drugbank-id>
      <name>Droperidol</name>
      <description>Droperidol may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00502</drugbank-id>
      <name>Haloperidol</name>
      <description>Haloperidol may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00541</drugbank-id>
      <name>Vincristine</name>
      <description>Vincristine may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00623</drugbank-id>
      <name>Fluphenazine</name>
      <description>Fluphenazine may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00649</drugbank-id>
      <name>Stavudine</name>
      <description>Stavudine may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00679</drugbank-id>
      <name>Thioridazine</name>
      <description>Thioridazine may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00680</drugbank-id>
      <name>Moricizine</name>
      <description>Moricizine may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00726</drugbank-id>
      <name>Trimipramine</name>
      <description>Trimipramine may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00734</drugbank-id>
      <name>Risperidone</name>
      <description>Risperidone may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00831</drugbank-id>
      <name>Trifluoperazine</name>
      <description>Trifluoperazine may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00850</drugbank-id>
      <name>Perphenazine</name>
      <description>Perphenazine may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00900</drugbank-id>
      <name>Didanosine</name>
      <description>Didanosine may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00924</drugbank-id>
      <name>Cyclobenzaprine</name>
      <description>Cyclobenzaprine may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00933</drugbank-id>
      <name>Mesoridazine</name>
      <description>Mesoridazine may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01063</drugbank-id>
      <name>Acetophenazine</name>
      <description>Acetophenazine may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01100</drugbank-id>
      <name>Pimozide</name>
      <description>Pimozide may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01190</drugbank-id>
      <name>Clindamycin</name>
      <description>Clindamycin may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01199</drugbank-id>
      <name>Tubocurarine</name>
      <description>Tubocurarine may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01242</drugbank-id>
      <name>Clomipramine</name>
      <description>Clomipramine may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01245</drugbank-id>
      <name>Decamethonium</name>
      <description>Decamethonium may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01246</drugbank-id>
      <name>Alimemazine</name>
      <description>Alimemazine may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01267</drugbank-id>
      <name>Paliperidone</name>
      <description>Paliperidone may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01356</drugbank-id>
      <name>Lithium cation</name>
      <description>Lithium cation may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01598</drugbank-id>
      <name>Imipenem</name>
      <description>Imipenem may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01608</drugbank-id>
      <name>Periciazine</name>
      <description>Periciazine may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01614</drugbank-id>
      <name>Acepromazine</name>
      <description>Acepromazine may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01615</drugbank-id>
      <name>Aceprometazine</name>
      <description>Aceprometazine may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01618</drugbank-id>
      <name>Molindone</name>
      <description>Molindone may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01621</drugbank-id>
      <name>Pipotiazine</name>
      <description>Pipotiazine may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01622</drugbank-id>
      <name>Thioproperazine</name>
      <description>Thioproperazine may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01623</drugbank-id>
      <name>Thiothixene</name>
      <description>Thiothixene may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01624</drugbank-id>
      <name>Zuclopenthixol</name>
      <description>Zuclopenthixol may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01627</drugbank-id>
      <name>Lincomycin</name>
      <description>Lincomycin may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04836</drugbank-id>
      <name>Amineptine</name>
      <description>Amineptine may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04872</drugbank-id>
      <name>Osanetant</name>
      <description>Osanetant may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04888</drugbank-id>
      <name>Bifeprunox</name>
      <description>Bifeprunox may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04946</drugbank-id>
      <name>Iloperidone</name>
      <description>Iloperidone may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05316</drugbank-id>
      <name>Pimavanserin</name>
      <description>Pimavanserin may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05687</drugbank-id>
      <name>BL-1020</name>
      <description>BL-1020 may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06016</drugbank-id>
      <name>Cariprazine</name>
      <description>Cariprazine may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06144</drugbank-id>
      <name>Sertindole</name>
      <description>Sertindole may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06216</drugbank-id>
      <name>Asenapine</name>
      <description>Asenapine may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06288</drugbank-id>
      <name>Amisulpride</name>
      <description>Amisulpride may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08815</drugbank-id>
      <name>Lurasidone</name>
      <description>Lurasidone may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08922</drugbank-id>
      <name>Perospirone</name>
      <description>Perospirone may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08927</drugbank-id>
      <name>Amperozide</name>
      <description>Amperozide may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08996</drugbank-id>
      <name>Dimetacrine</name>
      <description>Dimetacrine may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09000</drugbank-id>
      <name>Cyamemazine</name>
      <description>Cyamemazine may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09016</drugbank-id>
      <name>Butriptyline</name>
      <description>Butriptyline may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09128</drugbank-id>
      <name>Brexpiprazole</name>
      <description>Brexpiprazole may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09223</drugbank-id>
      <name>Blonanserin</name>
      <description>Sodium citrate may increase the neurotoxic activities of Blonanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09224</drugbank-id>
      <name>Melperone</name>
      <description>Sodium citrate may increase the neurotoxic activities of Melperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09225</drugbank-id>
      <name>Zotepine</name>
      <description>Sodium citrate may increase the neurotoxic activities of Zotepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09226</drugbank-id>
      <name>RP-5063</name>
      <description>Sodium citrate may increase the neurotoxic activities of RP-5063.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09275</drugbank-id>
      <name>Bismuth subcitrate potassium</name>
      <description>Sodium citrate may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09286</drugbank-id>
      <name>Pipamperone</name>
      <description>Sodium citrate may increase the neurotoxic activities of Pipamperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09289</drugbank-id>
      <name>Tianeptine</name>
      <description>Sodium citrate may increase the neurotoxic activities of Tianeptine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09307</drugbank-id>
      <name>Oxaprotiline</name>
      <description>Sodium citrate may increase the neurotoxic activities of Oxaprotiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11281</drugbank-id>
      <name>Bismuth subcarbonate</name>
      <description>Sodium citrate may increase the neurotoxic activities of Bismuth subcarbonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11376</drugbank-id>
      <name>Azaperone</name>
      <description>Sodium citrate may increase the neurotoxic activities of Azaperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11537</drugbank-id>
      <name>Pirlimycin</name>
      <description>Sodium citrate may increase the neurotoxic activities of Pirlimycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11540</drugbank-id>
      <name>Propiopromazine</name>
      <description>Sodium citrate may increase the neurotoxic activities of Propiopromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12273</drugbank-id>
      <name>Ecopipam</name>
      <description>Sodium citrate may increase the neurotoxic activities of Ecopipam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12401</drugbank-id>
      <name>Bromperidol</name>
      <description>Sodium citrate may increase the neurotoxic activities of Bromperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12518</drugbank-id>
      <name>Raclopride</name>
      <description>Sodium citrate may increase the neurotoxic activities of Raclopride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12710</drugbank-id>
      <name>Perazine</name>
      <description>Sodium citrate may increase the neurotoxic activities of Perazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12867</drugbank-id>
      <name>Benperidol</name>
      <description>Sodium citrate may increase the neurotoxic activities of Benperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12930</drugbank-id>
      <name>Opipramol</name>
      <description>Sodium citrate may increase the neurotoxic activities of Opipramol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12958</drugbank-id>
      <name>Prothipendyl</name>
      <description>Sodium citrate may increase the neurotoxic activities of Prothipendyl.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13025</drugbank-id>
      <name>Tiapride</name>
      <description>Sodium citrate may increase the neurotoxic activities of Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13114</drugbank-id>
      <name>Amitriptylinoxide</name>
      <description>Sodium citrate may increase the neurotoxic activities of Amitriptylinoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13209</drugbank-id>
      <name>Bismuth subnitrate</name>
      <description>Sodium citrate may increase the neurotoxic activities of Bismuth subnitrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13213</drugbank-id>
      <name>Butaperazine</name>
      <description>Sodium citrate may increase the neurotoxic activities of Butaperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13225</drugbank-id>
      <name>Dibenzepin</name>
      <description>Sodium citrate may increase the neurotoxic activities of Dibenzepin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13246</drugbank-id>
      <name>Quinupramine</name>
      <description>Sodium citrate may increase the neurotoxic activities of Quinupramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13256</drugbank-id>
      <name>Clothiapine</name>
      <description>Sodium citrate may increase the neurotoxic activities of Clothiapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13273</drugbank-id>
      <name>Sultopride</name>
      <description>Sodium citrate may increase the neurotoxic activities of Sultopride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13382</drugbank-id>
      <name>Chlorproethazine</name>
      <description>Sodium citrate may increase the neurotoxic activities of Chlorproethazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13384</drugbank-id>
      <name>Melitracen</name>
      <description>Sodium citrate may increase the neurotoxic activities of Melitracen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13403</drugbank-id>
      <name>Oxypertine</name>
      <description>Sodium citrate may increase the neurotoxic activities of Oxypertine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13411</drugbank-id>
      <name>Lofepramine</name>
      <description>Sodium citrate may increase the neurotoxic activities of Lofepramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13420</drugbank-id>
      <name>Thiazinam</name>
      <description>Sodium citrate may increase the neurotoxic activities of Thiazinam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13496</drugbank-id>
      <name>Iprindole</name>
      <description>Sodium citrate may increase the neurotoxic activities of Iprindole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13523</drugbank-id>
      <name>Veralipride</name>
      <description>Sodium citrate may increase the neurotoxic activities of Veralipride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13552</drugbank-id>
      <name>Trifluperidol</name>
      <description>Sodium citrate may increase the neurotoxic activities of Trifluperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13554</drugbank-id>
      <name>Moperone</name>
      <description>Sodium citrate may increase the neurotoxic activities of Moperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13557</drugbank-id>
      <name>Thiopropazate</name>
      <description>Sodium citrate may increase the neurotoxic activities of Thiopropazate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13584</drugbank-id>
      <name>Gallamine</name>
      <description>Sodium citrate may increase the neurotoxic activities of Gallamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13598</drugbank-id>
      <name>Diethyl ether</name>
      <description>Sodium citrate may increase the neurotoxic activities of Diethyl ether.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13665</drugbank-id>
      <name>Fluanisone</name>
      <description>Sodium citrate may increase the neurotoxic activities of Fluanisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13676</drugbank-id>
      <name>Mosapramine</name>
      <description>Sodium citrate may increase the neurotoxic activities of Mosapramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13782</drugbank-id>
      <name>Imipramine oxide</name>
      <description>Sodium citrate may increase the neurotoxic activities of Imipramine oxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13784</drugbank-id>
      <name>Dixyrazine</name>
      <description>Sodium citrate may increase the neurotoxic activities of Dixyrazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13841</drugbank-id>
      <name>Clopenthixol</name>
      <description>Sodium citrate may increase the neurotoxic activities of Clopenthixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13909</drugbank-id>
      <name>Bismuth subgallate</name>
      <description>Sodium citrate may increase the neurotoxic activities of Bismuth subgallate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13910</drugbank-id>
      <name>Valproate bismuth</name>
      <description>Sodium citrate may increase the neurotoxic activities of Valproate bismuth.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14185</drugbank-id>
      <name>Aripiprazole lauroxil</name>
      <description>Sodium citrate may increase the neurotoxic activities of Aripiprazole lauroxil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14651</drugbank-id>
      <name>Perphenazine enanthate</name>
      <description>Sodium citrate may increase the neurotoxic activities of Perphenazine enanthate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00781</drugbank-id>
      <name>Polymyxin B</name>
      <description>Sodium citrate may increase the neurotoxic activities of Polymyxin B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00246</drugbank-id>
      <name>Ziprasidone</name>
      <description>Ziprasidone may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>Amitriptyline may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>Clozapine may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00420</drugbank-id>
      <name>Promazine</name>
      <description>Promazine may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>Imipramine may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>Chlorpromazine may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00508</drugbank-id>
      <name>Triflupromazine</name>
      <description>Triflupromazine may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>Nortriptyline may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00543</drugbank-id>
      <name>Amoxapine</name>
      <description>Amoxapine may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00875</drugbank-id>
      <name>Flupentixol</name>
      <description>Flupentixol may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01069</drugbank-id>
      <name>Promethazine</name>
      <description>Promethazine may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>Doxepin may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>Desipramine may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01238</drugbank-id>
      <name>Aripiprazole</name>
      <description>Aripiprazole may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01239</drugbank-id>
      <name>Chlorprothixene</name>
      <description>Chlorprothixene may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01403</drugbank-id>
      <name>Methotrimeprazine</name>
      <description>Methotrimeprazine may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04842</drugbank-id>
      <name>Fluspirilene</name>
      <description>Fluspirilene may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09167</drugbank-id>
      <name>Dosulepin</name>
      <description>Sodium citrate may increase the neurotoxic activities of Dosulepin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12093</drugbank-id>
      <name>Tetrahydropalmatine</name>
      <description>Sodium citrate may increase the neurotoxic activities of Tetrahydropalmatine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13791</drugbank-id>
      <name>Penfluridol</name>
      <description>Sodium citrate may increase the neurotoxic activities of Penfluridol.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>-0.55</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-0.54</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>7.37e+01 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-1.3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>trisodium 2-hydroxypropane-1,2,3-tricarboxylate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>trisodium citrate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>258.068</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>257.97283534</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C6H5Na3O7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C6H8O7.3Na/c7-3(8)1-6(13,5(11)12)2-4(9)10;;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;/q;3*+1/p-3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>HRXKRNGNAMMEHJ-UHFFFAOYSA-K</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>140.62</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>68.14</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>14.23</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>3.05</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-4.2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>-3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>29.4g/L</value>
      <source>MSDS</source>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>300</value>
      <source>MSDS</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>10290</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>11969</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>53258</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>6224</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>310265067</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D05855</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>5989</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Sodium_citrate</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1355</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters>
    <transporter position="1">
      <id>BE0008678</id>
      <name>Mitochondrial 2-oxodicarboxylate carrier</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links>
          <link>
            <ref-id>L792</ref-id>
            <title>UniProt: Mitochondrial 2-oxodicarboxylate carrier</title>
            <url>http://www.uniprot.org/uniprot/Q9BQT8</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>no</known-action>
      <polypeptide id="Q9BQT8" source="Swiss-Prot">
        <name>Mitochondrial 2-oxodicarboxylate carrier</name>
        <general-function>Dicarboxylic acid transmembrane transporter activity</general-function>
        <specific-function>Transports C5-C7 oxodicarboxylates across the inner membranes of mitochondria. Can transport 2-oxoadipate, 2-oxoglutarate, adipate, glutarate, and to a lesser extent, pimelate, 2-oxopimelate, 2-aminoadipate, oxaloacetate, and citrate.</specific-function>
        <gene-name>SLC25A21</gene-name>
        <locus/>
        <cellular-location>Mitochondrion inner membrane</cellular-location>
        <transmembrane-regions>17-37
70-89
113-133
167-187
205-225
277-297</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>33302.88</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:14411</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9BQT8</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ODC_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ODC</synonym>
          <synonym>Solute carrier family 25 member 21</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0049433|Mitochondrial 2-oxodicarboxylate carrier
MSAKPEVSLVREASRQIVAGGSAGLVEICLMHPLDVVKTRFQIQRCATDPNSYKSLVDSF
RMIFQMEGLFGFYKGILPPILAETPKRAVKFFTFEQYKKLLGYVSLSPALTFAIAGLGSG
LTEAIVVNPFEVVKVGLQANRNTFAEQPSTVGYARQIIKKEGWGLQGLNKGLTATLGRHG
VFNMVYFGFYYNVKNMIPVNKDPILEFWRKFGIGLLSGTIASVINIPFDVAKSRIQGPQP
VPGEIKYRTCFKTMATVYQEEGILALYKGLLPKIMRLGPGGAVMLLVYEYTYSWLQENW</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0049434|Mitochondrial 2-oxodicarboxylate carrier (SLC25A21)
ATGTCCGCCAAGCCTGAAGTCAGCTTAGTGCGCGAGGCTTCTCGGCAGATCGTGGCCGGT
GGTTCTGCAGGTCTTGTAGAAATTTGCCTGATGCACCCCCTAGATGTGGTGAAAACCAGG
TTTCAGATTCAGAGATGTGCAACCGATCCAAACAGTTATAAAAGCTTGGTAGACAGCTTT
CGAATGATTTTCCAAATGGAAGGGTTATTTGGTTTTTACAAGGGAATTCTGCCACCTATC
TTGGCTGAAACCCCAAAAAGAGCAGTGAAGTTTTTCACCTTTGAGCAGTACAAGAAATTG
CTGGGATATGTGTCACTGTCACCAGCATTGACATTCGCCATTGCTGGATTGGGATCTGGA
CTAACAGAAGCCATTGTAGTTAACCCTTTTGAGGTAGTAAAAGTTGGCTTGCAAGCAAAT
CGGAACACATTTGCAGAGCAACCATCCACTGTGGGTTATGCAAGACAAATCATTAAGAAG
GAAGGCTGGGGACTCCAGGGCCTCAACAAAGGATTAACTGCAACTTTGGGACGACATGGA
GTTTTCAACATGGTTTATTTTGGCTTCTACTACAATGTCAAAAACATGATTCCTGTCAAT
AAGGATCCAATCTTGGAGTTTTGGAGAAAATTTGGGATTGGTCTTCTCTCGGGGACAATA
GCCTCAGTCATTAACATCCCTTTTGATGTTGCCAAAAGTAGGATTCAAGGGCCTCAACCA
GTTCCTGGAGAGATCAAGTACAGAACCTGTTTTAAAACAATGGCAACAGTCTATCAGGAA
GAAGGGATTTTAGCTTTGTACAAAGGCCTGCTTCCCAAGATTATGAGACTTGGACCAGGT
GGTGCAGTGATGCTGCTGGTTTATGAATACACCTATTCATGGCTTCAAGAGAACTGGTGA
</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00153</identifier>
            <name>Mito_carr</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrial inner membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>alpha-ketoglutarate transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>dicarboxylic acid transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dicarboxylic acid transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lysine catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mitochondrial transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="2">
      <id>BE0000447</id>
      <name>Solute carrier family 13 member 2</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links>
          <link>
            <ref-id>L793</ref-id>
            <title>UniProt: Solute carrier family 13 member 2</title>
            <url>http://www.uniprot.org/uniprot/Q13183</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>no</known-action>
      <polypeptide id="Q13183" source="Swiss-Prot">
        <name>Solute carrier family 13 member 2</name>
        <general-function>Low-affinity sodium:dicarboxylate symporter activity</general-function>
        <specific-function>Cotransport of sodium ions and dicarboxylates such as succinate and citrate.</specific-function>
        <gene-name>SLC13A2</gene-name>
        <locus>17p13.2</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>13-33
53-73
86-106
114-134
221-241
274-294
324-344
371-391
450-470
482-502
511-531
545-565</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>7.01</theoretical-pi>
        <molecular-weight>64409.495</molecular-weight>
        <chromosome-location>17</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10917</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>SLC13A2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U26209</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>1098557</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q13183</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>S13A2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Na(+)/dicarboxylate cotransporter 1</synonym>
          <synonym>NaDC-1</synonym>
          <synonym>NADC1</synonym>
          <synonym>Renal sodium/dicarboxylate cotransporter</synonym>
          <synonym>SDCT1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000891|Solute carrier family 13 member 2
MATCWQALWAYRSYLIVFFVPILLLPLPILVPSKEAYCAYAIILMALFWCTEALPLAVTA
LFPLILFPMMGIVDASEVAVEYLKDSNLLFFGGLLVAIAVEHWNLHKRIALRVLLIVGVR
PAPLILGFMLVTAFLSMWISNTATSAMMVPIAHAVLDQLHSSQASSNVEEGSNNPTFELQ
EPSPQKEVTKLDNGQALPVTSASSEGRAHLSQKHLHLTQCMSLCVCYSASIGGIATLTGT
APNLVLQGQINSLFPQNGNVVNFASWFSFAFPTMVILLLLAWLWLQILFLGFNFRKNFGI
GEKMQEQQQAAYCVIQTEHRLLGPMTFAEKAISILFVILVLLWFTREPGFFLGWGNLAFP
NAKGESMVSDGTVAIFIGIIMFIIPSKFPGLTQDPENPGKLKAPLGLLDWKTVNQKMPWN
IVLLLGGGYALAKGSERSGLSEWLGNKLTPLQSVPAPAIAIILSLLVATFTECTSNVATT
TIFLPILASMAQAICLHPLYVMLPCTLATSLAFMLPVATPPNAIVFSFGDLKVLDMARAG
FLLNIIGVLIIALAINSWGIPLFSLHSFPSWAQSNTTAQCLPSLANTTTPSP</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016096|Solute carrier family 13 member 2 (SLC13A2)
ATGGCCACCTGCTGGCAGGCCCTGTGGGCCTATCGCTCCTACCTGATCGTGTTCTTCGTG
CCCATTCTCCTGCTGCCTCTGCCCATCCTCGTCCCCAGTAAGGAGGCCTACTGCGCGTAT
GCCATCATCCTCATGGCGCTCTTCTGGTGCACTGAGGCCCTGCCCCTGGCCGTCACTGCC
CTCTTCCCCTTAATCCTGTTCCCTATGATGGGCATCGTGGATGCCTCTGAGATCATTCAG
AGACCATTTCCATCCAGTTTCGAGAGCCCAGGGGAATGCCAGTCTGTGGGAATGTCAGTG
ACTGCATCCCATAACCTCGGGGGCACCGTGGGAGACTCCAGGGTCTTCCCGCCGCTCAGC
CATGTCTCCACCTGCCAGGTTGCCGTCGAGTATCTTAAGGACTCCAACCTCCTGTTCTTC
GGGGGGCTGCTGGTGGCCATCGCGGTGGAACACTGGAACCTGCATAAACGCATCGCCCTC
CGTGTCCTCCTCATCGTTGGGGTGCGGCCTGCCCCGCTAATCCTGGGCTTCATGCTGGTC
ACGGCCTTCCTGTCCATGTGGATCAGCAACACGGCCACCTCAGCCATGATGGTGCCCATC
GCACATGCCGTCCTGGACCAGCTGCACAGCTCGCAAGCCAGCAGCAACGTCGAGGAGGGC
AGCAACAACCCCACCTTCGAGCTCCAGGAACCAAGTCCCCAGAAGGAGGTGACCAAGCTT
GATAATGGGCAGGCCCTCCCTGTCACGTCTGCCTCTTCGGAGGGGAGGGCACATCTCAGC
CAGAAGCATCTCCACCTCACCCAGTGCATGAGCCTGTGCGTGTGCTACTCCGCCAGCATC
GGGGGCATCGCCACGCTGACTGGCACCGCACCCAACCTGGTGCTGCAAGGCCAGATCAAC
TCGCTCTTCCCCCAAAACGGCAACGTGGTGAACTTCGCCTCCTGGTTCAGCTTCGCCTTC
CCCACCATGGTCATCTTGCTGCTGCTGGCCTGGTTGTGGCTGCAGATCCTCTTCCTGGGC
TTCAACTTCCGGAAGAACTTTGGCATTGGGGAAAAGATGCAGGAGCAACAGCAGGCAGCC
TACTGCGTCATCCAGACCGAGCACAGGCTGCTGGGCCCCATGACCTTTGCAGAAAAGGCC
ATCAGCATCCTATTCGTCATCCTGGTGCTGCTCTGGTTCACCCGGGAGCCGGGCTTTTTT
CTTGGCTGGGGCAATTTGGCTTTTCCCAATGCCAAGGGGGAGAGCATGGTGTCCGATGGG
ACAGTGGCCATCTTCATCGGCATAATTATGTTCATCATACCCTCCAAGTTCCCAGGGCTG
ACCCAGGACCCAGAAAACCCAGGGAAGCTGAAGGCCCCTCTTGGCCTCCTCGACTGGAAG
ACGGTGAACCAGAAGATGCCGTGGAATATCGTGTTATTGCTGGGTGGTGGCTATGCCCTG
GCCAAGGGCAGTGAGCGATCGGGCCTGTCAGAGTGGCTGGGAAACAAGCTGACCCCACTG
CAGAGTGTGCCAGCTCCAGCCATTGCCATCATCCTCTCCCTCCTGGTGGCCACCTTCACC
GAGTGCACTAGCAACGTGGCCACCACTACGATCTTCCTGCCCATCCTAGCCTCCATGGCC
CAGGCCATCTGCCTCCACCCTCTCTACGTCATGCTCCCCTGCACTCTGGCCACCTCCCTG
GCCTTCATGTTGCCTGTGGCCACCCCGCCCAATGCCATCGTCTTCTCTTTCGGGGACCTC
AAAGTGTTGGATATGGCCCGGGCAGGATTCCTCCTCAACATCATTGGAGTCCTGATCATC
GCACTGGCCATCAACAGCTGGGGCATCCCCCTCTTCAGCCTGCACTCTTTCCCCTCCTGG
GCACAGTCCAACACCACAGCCCAGTGCCTGCCAAGCCTGGCCAACACCACCACACCAAGC
CCCTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00939</identifier>
            <name>Na_sulph_symp</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>low-affinity sodium</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>anion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dicarboxylic acid transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="3">
      <id>BE0008677</id>
      <name>Solute carrier family 13 member 5</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A19417</ref-id>
            <pubmed-id>12177002</pubmed-id>
            <citation>Inoue K, Zhuang L, Maddox DM, Smith SB, Ganapathy V: Structure, function, and expression pattern of a novel sodium-coupled citrate transporter (NaCT) cloned from mammalian brain. J Biol Chem. 2002 Oct 18;277(42):39469-76. Epub 2002 Aug 11.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>no</known-action>
      <polypeptide id="Q86YT5" source="Swiss-Prot">
        <name>Solute carrier family 13 member 5</name>
        <general-function>Succinate transmembrane transporter activity</general-function>
        <specific-function>High-affinity sodium/citrate cotransporter that mediates citrate entry into cells. The transport process is electrogenic; it is the trivalent form of citrate rather than the divalent form that is recognized as a substrate. May facilitate the utilization of circulating citrate for the generation of metabolic energy and for the synthesis of fatty acids and cholesterol.</specific-function>
        <gene-name>SLC13A5</gene-name>
        <locus/>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>13-33
53-73
80-100
124-144
215-235
252-272
311-331
353-373
406-426
439-459
487-507
528-548</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>63061.605</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:23089</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q86YT5</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>S13A5_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Na(+)/citrate cotransporter</synonym>
          <synonym>NACT</synonym>
          <synonym>Sodium-coupled citrate transporter</synonym>
          <synonym>Sodium-dependent citrate transporter</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0049431|Solute carrier family 13 member 5
MASALSYVSKFKSFVILFVTPLLLLPLVILMPAKFVRCAYVIILMAIYWCTEVIPLAVTS
LMPVLLFPLFQILDSRQVCVQYMKDTNMLFLGGLIVAVAVERWNLHKRIALRTLLWVGAK
PARLMLGFMGVTALLSMWISNTATTAMMVPIVEAILQQMEATSAATEAGLELVDKGKAKE
LPGSQVIFEGPTLGQQEDQERKRLCKAMTLCICYAASIGGTATLTGTGPNVVLLGQMNEL
FPDSKDLVNFASWFAFAFPNMLVMLLFAWLWLQFVYMRFNFKKSWGCGLESKKNEKAALK
VLQEEYRKLGPLSFAEINVLICFFLLVILWFSRDPGFMPGWLTVAWVEGETKYVSDATVA
IFVATLLFIVPSQKPKFNFRSQTEEERKTPFYPPPLLDWKVTQEKVPWGIVLLLGGGFAL
AKGSEASGLSVWMGKQMEPLHAVPPAAITLILSLLVAVFTECTSNVATTTLFLPIFASMS
RSIGLNPLYIMLPCTLSASFAFMLPVATPPNAIVFTYGHLKVADMVKTGVIMNIIGVFCV
FLAVNTWGRAIFDLDHFPDWANVTHIET</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0049432|Solute carrier family 13 member 5 (SLC13A5)
ATGGCCTCGGCGCTGAGCTATGTCTCCAAGTTCAAGTCCTTCGTGATCTTGTTCGTCACC
CCGCTCCTGCTGCTGCCACTCGTCATTCTGATGCCCGCCAAGTTTGTCAGGTGTGCCTAC
GTCATCATCCTCATGGCCATTTACTGGTGCACAGAAGTCATCCCTCTGGCTGTCACCTCT
CTCATGCCTGTCTTGCTTTTCCCACTCTTCCAGATTCTGGACTCCAGGCAGGTGTGTGTC
CAGTACATGAAGGACACCAACATGCTGTTCCTGGGCGGCCTCATCGTGGCCGTGGCTGTG
GAGCGCTGGAACCTGCACAAGAGGATCGCCCTGCGCACGCTCCTCTGGGTGGGGGCCAAG
CCTGCACGGCTGATGCTGGGCTTCATGGGCGTCACAGCCCTCCTGTCCATGTGGATCAGT
AACACGGCAACCACGGCCATGATGGTGCCCATCGTGGAGGCCATATTGCAGCAGATGGAA
GCCACAAGCGCAGCCACCGAGGCCGGCCTGGAGCTGGTGGACAAGGGCAAGGCCAAGGAG
CTGCCAGGGAGTCAAGTGATTTTTGAAGGCCCCACTCTGGGGCAGCAGGAAGACCAAGAG
CGGAAGAGGTTGTGTAAGGCCATGACCCTGTGCATCTGCTACGCGGCCAGCATCGGGGGC
ACCGCCACCCTGACCGGGACGGGACCCAACGTGGTGCTCCTGGGCCAGATGAACGAGTTG
TTTCCTGACAGCAAGGACCTCGTGAACTTTGCTTCCTGGTTTGCATTTGCCTTTCCCAAC
ATGCTGGTGATGCTGCTGTTCGCCTGGCTGTGGCTCCAGTTTGTTTACATGAGATTCAAT
TTTAAAAAGTCCTGGGGCTGCGGGCTAGAGAGCAAGAAAAACGAGAAGGCTGCCCTCAAG
GTGCTGCAGGAGGAGTACCGGAAGCTGGGGCCCTTGTCCTTCGCGGAGATCAACGTGCTG
ATCTGCTTCTTCCTGCTGGTCATCCTGTGGTTCTCCCGAGACCCCGGCTTCATGCCCGGC
TGGCTGACTGTTGCCTGGGTGGAGGGTGAGACAAAGTATGTCTCCGATGCCACTGTGGCC
ATCTTTGTGGCCACCCTGCTATTCATTGTGCCTTCACAGAAGCCCAAGTTTAACTTCCGC
AGCCAGACTGAGGAAGAAAGGAAAACTCCATTTTATCCCCCTCCCCTGCTGGATTGGAAG
GTAACCCAGGAGAAAGTGCCCTGGGGCATCGTGCTGCTACTAGGGGGCGGATTTGCTCTG
GCTAAAGGATCCGAGGCCTCGGGGCTGTCCGTGTGGATGGGGAAGCAGATGGAGCCCTTG
CACGCAGTGCCCCCGGCAGCCATCACCTTGATCTTGTCCTTGCTCGTTGCCGTGTTCACT
GAGTGCACAAGCAACGTGGCCACCACCACCTTGTTCCTGCCCATCTTTGCCTCCATGTCT
CGCTCCATCGGCCTCAATCCGCTGTACATCATGCTGCCCTGTACCCTGAGTGCCTCCTTT
GCCTTCATGTTGCCTGTGGCCACCCCTCCAAATGCCATCGTGTTCACCTATGGGCACCTC
AAGGTTGCTGACATGGTGAAAACAGGAGTCATAATGAACATAATTGGAGTCTTCTGTGTG
TTTTTGGCTGTCAACACCTGGGGACGGGCCATATTTGACTTGGATCATTTCCCTGACTGG
GCTAATGTGACACATATTGAGACTTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00939</identifier>
            <name>Na_sulph_symp</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>citrate transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>succinate transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>citrate transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>tricarboxylic acid transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="4">
      <id>BE0008676</id>
      <name>Tricarboxylate transport protein, mitochondrial</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A19418</ref-id>
            <pubmed-id>20686672</pubmed-id>
            <citation>Sun J, Aluvila S, Kotaria R, Mayor JA, Walters DE, Kaplan RS: Mitochondrial and Plasma Membrane Citrate Transporters: Discovery of Selective Inhibitors and Application to Structure/Function Analysis. Mol Cell Pharmacol. 2010;2(3):101-110.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>no</known-action>
      <polypeptide id="P53007" source="Swiss-Prot">
        <name>Tricarboxylate transport protein, mitochondrial</name>
        <general-function>Tricarboxylic acid transmembrane transporter activity</general-function>
        <specific-function>Involved in citrate-H(+)/malate exchange. Important for the bioenergetics of hepatic cells as it provides a carbon source for fatty acid and sterol biosyntheses, and NAD(+) for the glycolytic pathway.</specific-function>
        <gene-name>SLC25A1</gene-name>
        <locus/>
        <cellular-location>Mitochondrion inner membrane</cellular-location>
        <transmembrane-regions>29-46
86-105
129-143
183-202
224-241
278-297</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>34012.46</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10979</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P53007</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>TXTP_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Citrate transport protein</synonym>
          <synonym>CTP</synonym>
          <synonym>SLC20A3</synonym>
          <synonym>Solute carrier family 25 member 1</synonym>
          <synonym>Tricarboxylate carrier protein</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0049429|Tricarboxylate transport protein, mitochondrial
MPAPRAPRALAAAAPASGKAKLTHPGKAILAGGLAGGIEICITFPTEYVKTQLQLDERSH
PPRYRGIGDCVRQTVRSHGVLGLYRGLSSLLYGSIPKAAVRFGMFEFLSNHMRDAQGRLD
STRGLLCGLGAGVAEAVVVVCPMETIKVKFIHDQTSPNPKYRGFFHGVREIVREQGLKGT
YQGLTATVLKQGSNQAIRFFVMTSLRNWYRGDNPNKPMNPLITGVFGAIAGAASVFGNTP
LDVIKTRMQGLEAHKYRNTWDCGLQILKKEGLKAFYKGTVPRLGRVCLDVAIVFVIYDEV
VKLLNKVWKTD</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0049430|Tricarboxylate transport protein, mitochondrial (SLC25A1)
ATGCCCGCGCCCCGCGCCCCGCGCGCTCTGGCGGCCGCCGCGCCCGCGTCCGGGAAGGCC
AAGCTGACGCACCCGGGGAAGGCGATCCTGGCAGGCGGCCTGGCGGGTGGCATCGAGATC
TGCATCACCTTCCCCACCGAGTACGTGAAGACGCAGCTGCAGCTGGACGAGCGCTCGCAC
CCGCCGCGGTACCGGGGCATCGGGGACTGCGTGCGGCAGACGGTTCGCAGCCATGGCGTC
CTGGGCCTGTACCGCGGCCTTAGCTCCCTGCTCTACGGTTCCATCCCCAAGGCGGCCGTC
AGGTTTGGAATGTTCGAGTTCCTCAGCAACCACATGCGGGATGCCCAGGGACGGCTGGAC
AGCACGCGTGGGCTGCTGTGCGGCCTGGGCGCTGGCGTGGCCGAGGCCGTGGTGGTCGTG
TGCCCCATGGAGACCATCAAGGTGAAGTTCATCCACGACCAGACCTCCCCAAACCCCAAG
TACAGAGGATTCTTCCACGGGGTTAGGGAGATTGTGCGGGAACAAGGGCTGAAGGGGACG
TACCAGGGCCTCACAGCCACTGTCCTGAAGCAGGGCTCGAACCAGGCCATCCGCTTCTTC
GTCATGACCTCCCTGCGCAACTGGTACCGAGGGGACAACCCCAACAAGCCCATGAACCCT
CTGATCACTGGGGTCTTCGGAGCTATTGCAGGCGCAGCCAGTGTCTTTGGAAACACTCCT
CTGGATGTGATTAAGACCCGGATGCAGGGCCTGGAGGCGCACAAATACCGGAACACGTGG
GACTGCGGCTTGCAGATCCTGAAGAAGGAGGGGCTCAAGGCATTCTACAAGGGCACTGTC
CCCCGCCTGGGCCGGGTCTGCCTGGATGTGGCCATAGTGTTTGTCATCTATGATGAAGTG
GTGAAGCTGCTCAACAAAGTGTGGAAGACGGACTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00153</identifier>
            <name>Mito_carr</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrial inner membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>citrate transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>tricarboxylic acid transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gluconeogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>long-chain fatty-acyl-CoA biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mitochondrial citrate transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
  </transporters>
</drug>